Search Result
Results for "
Human antibodies
" in MedChemExpress (MCE) Product Catalog:
9
Biochemical Assay Reagents
1261
Inhibitory Antibodies
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P990496
-
COM701
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990615
-
LOP628 antibody
|
c-Kit
|
Inflammation/Immunology
|
Anti-c-Kit Antibody (LMJ729) (LOP628 antibody) is a CHO-expressed human antibody that targets SCFR/c-Kit/CD117. The predicted molecular weight (MW) of Anti-c-Kit Antibody (LMJ729) is 150 kDa. The isotype control for Anti-c-Kit Antibody (LMJ729) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990464
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990343
-
|
Beta-secretase
|
Inflammation/Immunology
|
Anti-BACE1 Antibody is a CHO-expressed human antibody that targets BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. The isotype control for Anti-BACE1 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990357
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990535
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990578
-
DS-6157 antibody
|
G Protein-coupled Receptor Kinase (GRK)
|
Inflammation/Immunology
|
Anti-GPR20 Antibody (DS-6157 antibody) is a human antibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990429
-
|
Ferroportin
|
Inflammation/Immunology
|
Anti-Hepcidin/HAMP Antibody is a CHO-expressed human antibody that targets Hepcidin/HAMP. Anti-Hepcidin/HAMP Antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990485
-
|
PCSK9
|
Inflammation/Immunology
|
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990540
-
CSL346
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990405
-
|
Ephrin Receptor
|
Inflammation/Immunology
|
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990325
-
|
ATP-binding cassette (ABC) transporters
|
Inflammation/Immunology
|
Anti-ABCB5 Antibody is a CHO-expressed human antibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990421
-
|
HBV
|
Inflammation/Immunology
|
Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990476
-
|
Notch
|
Inflammation/Immunology
|
The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990497
-
|
CGRP Receptor
|
Inflammation/Immunology
|
Anti-RAMP3 Antibody is a CHO expressed human antibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990520
-
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Anti-TLR7 Antibody is a CHO-expressed human antibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990351
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990389
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990468
-
|
MMP
|
Inflammation/Immunology
|
Anti-MMP9 Antibody is a CHO-expressed human antibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990513
-
|
Microtubule/Tubulin
|
Inflammation/Immunology
|
The Anti-STOP1 Antibody is a human antibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990418
-
|
Smo
|
Inflammation/Immunology
|
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990510
-
|
Ferroportin
|
Inflammation/Immunology
|
Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO, targeting SLC40A1. The predicted molecular weight (MW) of Anti-SLC40A1 Antibody is 150 kDa.
|
-
-
- HY-P990504
-
|
PAI-1
|
Inflammation/Immunology
|
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990461
-
MSC-1
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-LIF Antibody (MSC-1) is a CHO-expressed human antibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990533
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-TPSAB1 Antibody is a CHO-expressed human antibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990481
-
|
PACAP Receptor
|
Inflammation/Immunology
|
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990534
-
K1-70
|
TSH Receptor
|
Inflammation/Immunology
|
Anti-TSHR Antibody (K1-70) is a CHO-expressed human antibody that targets TSHR. Anti-TSHR Antibody (K1-70) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.54 kDa. For the isotype control of Anti-TSHR Antibody (K1-70), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990495
-
|
Phosphatase
|
Inflammation/Immunology
|
Anti-PTPRC/CD45 Antibody is a CHO-expressed human antibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990442
-
CNTO 607
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990446
-
DISC0280
|
Interleukin Related
|
Inflammation/Immunology
|
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990529
-
|
TNF Receptor
|
Inflammation/Immunology
|
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed human antibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990471
-
|
Tyrosinase
|
Inflammation/Immunology
|
The Anti-MSPR/RON/CD136 Antibody is a human antibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990327
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990480
-
|
LDLR
|
Inflammation/Immunology
|
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990466
-
|
Mesothelin
|
Inflammation/Immunology
|
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990431
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990366
-
|
Glycosidase
|
Inflammation/Immunology
|
The Anti-CHI3L1 Antibody is a human antibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990368
-
AB1-11
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990374
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990532
-
|
Wnt
|
Inflammation/Immunology
|
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990460
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990544
-
AJW 200; AJvW 2
|
Integrin
|
Inflammation/Immunology
|
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990467
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990474
-
|
Trk Receptor
|
Inflammation/Immunology
|
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2a heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990395
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990425
-
|
Adenylate Cyclase
|
Inflammation/Immunology
|
Anti-GPR73/PROKR1 Antibody is a CHO-expressed human antibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990436
-
|
Integrin
|
Inflammation/Immunology
|
The Anti-ICAM3/CD50 Antibody is a human antibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990530
-
hMAK195
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990392
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990528
-
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990381
-
|
c-Fms
|
Inflammation/Immunology
|
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990524
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990352
-
|
Scavenger Receptor Class B type I (SR-BI)
|
Inflammation/Immunology
|
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990501
-
|
Wnt
β-catenin
|
Inflammation/Immunology
|
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990579
-
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990664
-
SC-005 antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990454
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
The Anti-INHBB/Activin B Antibody is a human antibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990478
-
|
CRAC Channel
|
Inflammation/Immunology
|
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990452
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990523
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990349
-
|
CD19
|
Inflammation/Immunology
|
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990393
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL9 Antibody is a humanized antibody expressed in CHO cells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990419
-
|
Amino Acid Decarboxylase
|
Inflammation/Immunology
|
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990439
-
|
IFNAR
|
Inflammation/Immunology
|
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990360
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990337
-
|
Chloride Channel
|
Inflammation/Immunology
|
Anti-ANO1/TMEM16A Antibody is a CHO-expressed human antibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990502
-
|
Sodium Channel
|
Inflammation/Immunology
|
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990391
-
|
CXCR
|
Inflammation/Immunology
|
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990364
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990400
-
|
Discoidin Domain Receptor
|
Inflammation/Immunology
|
Anti-DDR1/CD167a Antibody is a CHO-expressed human antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990516
-
|
PKA
|
Inflammation/Immunology
|
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990519
-
CNTO5429
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed human antibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990408
-
|
EGFR
|
Inflammation/Immunology
|
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed human antibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990503
-
|
Sodium Channel
|
Inflammation/Immunology
|
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990390
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990517
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990372
-
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990344
-
|
Bcl-2 Family
|
Inflammation/Immunology
|
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990505
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990451
-
SNG-CD123A
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed human antibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990332
-
CNTO 2125
|
Amyloid-β
|
Inflammation/Immunology
|
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990353
-
TRX1
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990403
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990627
-
MEDI-547 antibody
|
Ephrin Receptor
|
Inflammation/Immunology
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990630
-
OBT076
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
The Anti-LY75/CD205 Antibody (MEN1309) is a human antibody expressed in CHO cells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990479
-
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
|
Anti-OX2R/CD200R1 Antibody is a CHO-expressed human antibody that targets OX2R/CD200R1. The predicted molecular weight (MW) of Anti-OX2R/CD200R1 Antibody is 146.58 kDa. The isotype control for Anti-OX2R/CD200R1 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990417
-
|
Antifolate
|
Inflammation/Immunology
|
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990398
-
|
Integrin
|
Inflammation/Immunology
|
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990426
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990459
-
|
Kallikrein
|
Inflammation/Immunology
|
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990394
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990340
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990369
-
AB3-7
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991075
-
|
NAMPT
|
Inflammation/Immunology
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990531
-
|
TNF Receptor
|
Inflammation/Immunology
|
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990415
-
|
FGFR
|
Inflammation/Immunology
|
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990542
-
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990413
-
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990434
-
|
Histone Methyltransferase
|
Inflammation/Immunology
|
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990326
-
Ab-14E1
|
TGF-β Receptor
|
Inflammation/Immunology
|
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed human antibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990472
-
H5B14
|
c-Met/HGFR
|
Inflammation/Immunology
|
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990397
-
FA19-1
|
VEGFR
|
Inflammation/Immunology
|
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990385
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHO cells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990362
-
|
Cadherin
|
Inflammation/Immunology
|
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990543
-
|
VEGFR
|
Inflammation/Immunology
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990387
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990486
-
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990618
-
|
Ferroportin
|
Inflammation/Immunology
|
LY2928057 is a CHO-expressed human antibody that targets SLC40A1/Ferroportin. The predicted molecular weight (MW) of LY2928057 is 150 kDa. The isotype control for LY2928057 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990378
-
|
Complement System
|
Inflammation/Immunology
|
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990411
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed human antibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990324
-
3F6-9G5
|
Adenosine Receptor
|
Inflammation/Immunology
|
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990653
-
|
CCR
|
Inflammation/Immunology
|
R707 is a human antibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990563
-
|
Interleukin Related
|
Inflammation/Immunology
|
CDP-484 is a CHO-expressed human antibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990598
-
BMS-986253; HuMax-IL-8
|
CXCR
|
Inflammation/Immunology
|
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990597
-
|
FGFR
|
Inflammation/Immunology
|
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990674
-
|
GLUT
|
Inflammation/Immunology
|
VB1-050 is a human antibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990319
-
|
NAMPT
|
Inflammation/Immunology
|
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). For other indications, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990623
-
BMS-936559
|
PD-1/PD-L1
|
Inflammation/Immunology
|
MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990657
-
RO5458640
|
TNF Receptor
|
Inflammation/Immunology
|
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990587
-
|
CD28
|
Inflammation/Immunology
|
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990669
-
|
Interleukin Related
|
Inflammation/Immunology
|
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990564
-
BAY-103356; CDP-571
|
TNF Receptor
|
Inflammation/Immunology
|
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P991120
-
|
TNF Receptor
|
Cancer
|
Balertatug is a human IgG1K antibody targeting CD70. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
-
- HY-P990675
-
|
VEGFR
|
Inflammation/Immunology
|
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990591
-
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990614
-
|
Myosin
|
Inflammation/Immunology
|
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990611
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990589
-
|
Trk Receptor
|
Inflammation/Immunology
|
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990608
-
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
|
CD3
|
Inflammation/Immunology
|
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990620
-
|
VEGFR
|
Inflammation/Immunology
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990677
-
|
CCR
|
Inflammation/Immunology
|
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990561
-
|
Interleukin Related
|
Inflammation/Immunology
|
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990638
-
|
CXCR
|
Inflammation/Immunology
|
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P991121
-
-
- HY-P990639
-
|
CXCR
|
Inflammation/Immunology
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990562
-
|
Interleukin Related
|
Inflammation/Immunology
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990672
-
U3-1784
1 Publications Verification
|
FGFR
|
Inflammation/Immunology
|
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990555
-
|
CD47
|
Inflammation/Immunology
|
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990645
-
|
Cadherin
|
Inflammation/Immunology
|
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990547
-
|
Interleukin Related
|
Inflammation/Immunology
|
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990647
-
|
Interleukin Related
|
Inflammation/Immunology
|
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990313
-
|
CXCR
Interleukin Related
|
Inflammation/Immunology
|
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990559
-
|
TNF Receptor
|
Inflammation/Immunology
|
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990676
-
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990321
-
MEDI 8968
|
Interleukin Related
|
Inflammation/Immunology
|
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990317
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990445
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-13Ra2/CD213a2 is a CHO-expressed human antibody that targets IL-13Ra2/CD213a2. The predicted molecular weight (MW) of Anti-IL-13Ra2/CD213a2 is 150 kDa. The isotype control for Anti-IL-13Ra2/CD213a2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990622
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990649
-
TRU-015
|
CD20
|
Inflammation/Immunology
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9916
-
Anti-Human IL6Rα, Human Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
-
- HY-P9938
-
|
CGRP Receptor
|
Others
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
- HY-P99514
-
AGEN1884
|
CTLA-4
|
Cancer
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
- HY-P990643
-
|
Integrin
|
Inflammation/Immunology
|
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99057
-
CDX-1127
|
TNF Receptor
|
Cancer
|
Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
-
- HY-P99057A
-
|
TNF Receptor
|
Cancer
|
Varlilumab (anti-CD27) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
-
- HY-P99474
-
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
-
- HY-P991048
-
|
c-Fms
|
Cancer
|
AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P99040
-
JNJ-61610588
|
VISTA
|
Cancer
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
-
- HY-P9967
-
BIIB037
|
Amyloid-β
|
Neurological Disease
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99039
-
MEDI9447
|
CD73
|
Cancer
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
- HY-P99424
-
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
- HY-108810
-
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
- HY-P9974
-
OMP-18R5
|
Wnt
|
Cancer
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
- HY-P99041
-
ABX-EGF
|
EGFR
|
Cancer
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
- HY-P990574
-
|
Histone Methyltransferase
|
Inflammation/Immunology
|
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99041A
-
|
EGFR
|
Cancer
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99184
-
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
-
- HY-P990607
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P9957
-
ABthrax
|
Bacterial
|
Infection
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
- HY-P991119
-
|
Interleukin Related
|
Cancer
|
Balekafusp alfa is an IgG1K human antibody against IL-2 with anti-tumor activity. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
-
- HY-P99246
-
-
- HY-P990336
-
-
- HY-111965
-
-
- HY-P990373
-
-
- HY-P990335
-
-
- HY-P99431
-
Alomfilimab; SAR 445256
|
CD28
|
Inflammation/Immunology
Cancer
|
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
|
-
- HY-P99631
-
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
- HY-P991107
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-Dysadherin Antibody is a human antibody expressed in CHO cells, targeting dysadherin. Anti-Dysadherin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99271
-
Anti-Human F3 Recombinant Antibody
|
ADC Antibody
|
Cancer
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
-
- HY-P991109
-
PF-06647263 antibody
|
Transmembrane Glycoprotein
|
Neurological Disease
|
Anti-EFNA4 Antibody (PF-06647263 antibody) is a human antibody expressed in CHO cells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99632
-
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
- HY-P9805
-
MERS-3A1; MERS Antibody-3A1
|
SARS-CoV
|
Infection
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
- HY-P991108
-
HKT288 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a human antibody expressed in CHO cells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991102
-
|
CD3
|
Cancer
|
Anti-MUC17 Antibody is a human antibody expressed in CHO cells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991105
-
|
Dynamin
|
Others
|
Anti-Clathrin Heavy Chain Antibody is a human antibody expressed in CHO cells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991098
-
|
Trk Receptor
|
Neurological Disease
|
Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P991104
-
|
Integrin
|
Metabolic Disease
|
Anti-EMMPRIN/CD147 Antibody is a human antibody expressed in CHO cells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991103
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-25 Antibody is a human antibody expressed in CHO cells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991101
-
|
Amyloid-β
|
Neurological Disease
|
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991204
-
|
PSMA
|
Cancer
|
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99232
-
5F9 Monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
-
- HY-108730
-
Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
|
-
- HY-P991047
-
JR-141 antibody (uncoupled from iduronate 2-sulfatase)
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991100
-
|
Cadherin
|
Cancer
|
Anti-CDH17/Cadherin-17 Antibody (10C12) is a human antibody expressed in CHO cells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991196
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991082
-
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991197
-
|
CD3
|
Cancer
|
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-108730A
-
-
- HY-P99175
-
|
CD47
|
Cancer
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
-
- HY-P99996
-
-
- HY-P991202
-
|
TSH Receptor
|
Endocrinology
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991191
-
-
- HY-P99266
-
Anti-Human CD4 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
-
- HY-P991177
-
|
c-Met/HGFR
|
Cancer
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990964
-
-
- HY-P99205
-
|
ADC Antibody
|
Cancer
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-P99355
-
Anti-ACVR2B Reference Antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
-
- HY-P99447
-
|
Bacterial
|
Infection
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
- HY-P990058
-
-
- HY-P990967
-
-
- HY-P9908
-
-
- HY-P99699
-
-
- HY-P991182
-
|
CCR
|
Inflammation/Immunology
|
Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody that targets CCR8. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991072
-
MAPP-66
|
HIV
HSV
|
Infection
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99457
-
-
- HY-P990727
-
-
- HY-P990053
-
-
- HY-P991106
-
LY-3076226 antibody
|
FGFR
|
Cancer
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991175
-
-
- HY-P9909
-
-
- HY-P991185
-
|
c-Met/HGFR
|
Cancer
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991171
-
-
- HY-P991165
-
|
Fc Receptor (FcR)
|
Others
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99195
-
|
Trk Receptor
|
Inflammation/Immunology
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
-
- HY-P990754
-
|
c-Kit
|
Inflammation/Immunology
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99347
-
-
- HY-P99867
-
MEDI 573
|
IGF-1R
|
Others
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
-
- HY-P9S0009
-
-
- HY-P99200
-
-
- HY-P9927A
-
-
- HY-P99199
-
NI-0401
|
CD3
|
Inflammation/Immunology
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
- HY-P991174
-
|
TREM receptor
|
Inflammation/Immunology
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99263
-
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P99214
-
KBPA101
|
Bacterial
|
Infection
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
-
- HY-P99274
-
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
|
IGF-1R
|
Cancer
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
-
- HY-P99305
-
-
- HY-P9964
-
|
EGFR
|
Cancer
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
-
- HY-P990047
-
AMG133 antibody
|
GLP Receptor
|
Metabolic Disease
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
-
- HY-P990774
-
-
- HY-P990728
-
|
CD74
|
Inflammation/Immunology
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991115
-
|
Trk Receptor
|
Others
|
Amdokitug is an anti-MUSK human IgG1 λ monoclonal antibody. Recommend Isotype Controls: Human IgG1 Lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P991060
-
|
Transmembrane Glycoprotein
|
Cancer
|
Cergutuzumab is a fully human IgG1 antibody that targets CEACAM5. The isotype control for Cergutuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991117
-
|
Factor Xa
|
Cardiovascular Disease
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991164
-
|
Antifolate
|
Inflammation/Immunology
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99364
-
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
|
Cancer
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
-
- HY-P99408
-
-
- HY-P990074
-
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
|
-
- HY-P990725
-
|
SARS-CoV
|
Inflammation/Immunology
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991116
-
-
- HY-P990768
-
|
SARS-CoV
|
Inflammation/Immunology
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990898
-
-
- HY-P990705
-
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991187
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991170
-
|
SARS-CoV
|
Infection
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99533
-
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
-
- HY-P990043
-
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
-
- HY-P990750
-
|
LAG-3
|
Inflammation/Immunology
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990080
-
|
CTLA-4
|
Cancer
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
-
- HY-P99617
-
REGN3767
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
-
- HY-P990982
-
|
CCR
|
Inflammation/Immunology
|
HY-P990982 is an CCL17-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P991021
-
-
- HY-P990977
-
|
Nectin-4
|
Inflammation/Immunology
|
HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990998
-
-
- HY-P990918
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
HY-P990918 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990937
-
-
- HY-P991012
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991012 is an TNFRSF4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991035
-
-
- HY-P990941
-
|
Antifolate
|
Inflammation/Immunology
|
HY-P990941 is an FOLR1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99485
-
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
-
- HY-P990922
-
-
- HY-P990909
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990909 is an ERBB2-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990924
-
|
HBV
|
Inflammation/Immunology
|
HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990973
-
-
- HY-P990996
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
HY-P990996 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991010
-
|
CCR
|
Inflammation/Immunology
|
HY-P991010 is an CCL24-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991008
-
-
- HY-P99653
-
VAY-736
|
TNF Receptor
|
Cancer
|
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
|
-
- HY-P99604
-
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-P99646
-
MEDI6570
|
LOX-1
|
Metabolic Disease
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
-
- HY-P991059
-
|
Influenza Virus
|
Infection
|
VIS-410 is a fully human IgG1 antibody that targets influenza A virus. The isotype control for VIS-410 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99353
-
Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
-
- HY-P990756
-
|
SARS-CoV
|
Inflammation/Immunology
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990777
-
-
- HY-P990766
-
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P991031
-
-
- HY-P990711
-
|
SARS-CoV
|
Inflammation/Immunology
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P99272
-
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
-
- HY-P99156
-
BMS-986016
|
LAG-3
|
Cancer
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
-
- HY-P990068
-
SRF617
|
NTPDase
|
Cancer
|
Perenostobart is a human immunoglobulin G4-kappa, anti-ENTPD1/CD39 monoclonal antibody. Perenostobart is an immunostimulant and antineoplastic .
|
-
- HY-P9929
-
|
Bacterial
|
Infection
Inflammation/Immunology
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
-
- HY-P9918
-
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
- HY-P9903
-
BMS-936558; ONO-4538; MDX-1106
|
PD-1/PD-L1
|
Cancer
|
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
|
-
- HY-P99642
-
-
- HY-P991159
-
|
EGFR
|
Cancer
|
Ruzaltatug is a humanized IgG1 antibody targeting ERBB3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990968
-
|
LAG-3
|
Inflammation/Immunology
|
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990971
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990971 is an TNFRSF9-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990951
-
-
- HY-P990923
-
|
CCR
|
Inflammation/Immunology
|
HY-P990923 is an CCR8-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990976
-
|
LAG-3
|
Inflammation/Immunology
|
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99104
-
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
|
-
- HY-P99318
-
LT 1009; Anti-Human S1P Recombinant Antibody
|
LPL Receptor
|
Cancer
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
-
- HY-P99357
-
REGN1193; Anti-GCGR Reference Antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
-
- HY-P99188
-
CNTO 888
|
CCR
|
Cancer
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
|
-
- HY-P99586
-
REGN2222
|
RSV
|
Infection
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
-
- HY-P990947
-
-
- HY-P99286
-
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
-
- HY-P99703
-
17.1.41
|
HBV
|
Infection
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
-
- HY-P99194
-
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
-
- HY-P990911
-
-
- HY-P990900
-
|
CD73
|
Inflammation/Immunology
|
HY-P990900 is an NT5E-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990745
-
-
- HY-P991009
-
|
CD73
|
Inflammation/Immunology
|
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990975
-
-
- HY-P991064
-
3BNC-117
|
HIV
|
Infection
|
Lafuvitug (3BNC-117) is a fully human IgG1 antibody that targets envelope glycoprotein gp120 protein. The isotype control for Lafuvitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99473
-
BI-505
|
Integrin
|
Cancer
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
-
- HY-P99323
-
BTT 1023; Anti-Human AOC3 Recombinant Antibody
|
VAP-1
|
Inflammation/Immunology
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
-
- HY-P99870
-
ASLAN004; CSL-334; MK-6105
|
Interleukin Related
|
Others
|
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
|
-
- HY-P99167
-
HCD122
|
TNF Receptor
|
Cancer
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
-
- HY-P99622
-
IMC-20D7S
|
Tyrosinase
|
Cancer
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
- HY-P99262
-
BAX69; Anti-Human MIF Recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
- HY-P99307
-
AMG-203; Anti-Human CSF2 Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99760
-
BCD-145
|
CTLA-4
|
Cancer
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
- HY-P99288
-
Pamrevlumab; Anti-Human CTGF Recombinant Antibody
|
Apoptosis
|
Cancer
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P99484
-
AGEN 1181
|
CTLA-4
|
Cancer
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
-
- HY-P99320
-
OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody
|
Notch
|
Cancer
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
-
- HY-P991140
-
|
Claudin
|
Cancer
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-P990032
-
EOS-448; EOS884448; GSK4428859A
|
Transmembrane Glycoprotein
|
Cancer
|
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity .
|
-
- HY-P9925
-
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
-
- HY-P990954
-
|
CD47
|
Inflammation/Immunology
|
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9915
-
Anti-Human CD38, Human Antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P99275
-
Human Anti-ERBB3 Recombinant Antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
-
- HY-P99366A
-
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
-
- HY-P99695
-
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
-
- HY-P99423
-
ADG 20
|
SARS-CoV
|
Infection
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99168
-
|
IFNAR
|
Inflammation/Immunology
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
-
- HY-P99375
-
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
-
- HY-P990876
-
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
-
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-P990033
-
CC-95251; BMS-986351
|
CD47
|
Cancer
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
-
- HY-P990031
-
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
-
- HY-P99411
-
SHP647
|
Integrin
|
Inflammation/Immunology
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
-
- HY-P99207
-
KB 003
|
SARS-CoV
|
Cancer
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
-
- HY-P99900
-
MSL-109
|
CMV
|
Infection
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
-
- HY-P990921
-
-
- HY-P991126
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
-
- HY-P991139
-
|
CTLA-4
|
Cancer
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
-
- HY-P99461
-
ISU-104
|
EGFR
|
Cancer
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P990009
-
NIS-793
|
TGF-beta/Smad
|
Cancer
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
|
-
- HY-P9922
-
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-P991152
-
|
Interleukin Related
|
Inflammation/Immunology
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P9915A
-
Anti-Human CD38, Human Antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P991058
-
BMS-986315
|
Checkpoint Kinase (Chk)
|
Cancer
|
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99178
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
-
- HY-P99955
-
-
- HY-P99792
-
NM57; rhRIG
|
RABV
|
Infection
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
- HY-P990021
-
|
Bacterial
|
Others
|
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
|
-
- HY-P99257
-
ASKP 1240
|
TNF Receptor
|
Inflammation/Immunology
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: ?0.24?nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
|
-
- HY-P991071
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
AK-001 is a fully human IgG1 antibody that targets Siglec-8. VRC-01 can be used for the study of chronic rhinosinusitis with nasal polyps. The isotype control for AK-001 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991065
-
JNJ-375; JNJ-64179375; JNJ-9375
|
Thrombin
|
Cardiovascular Disease
|
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99260
-
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
|
TNF Receptor
|
Cancer
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
-
- HY-P991124
-
|
Factor XI
|
Cardiovascular Disease
|
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
|
-
- HY-P99036
-
-
- HY-P991135
-
|
CCR
|
Cancer
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P99764
-
REGN-3471
|
Filovirus
|
Infection
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
-
- HY-P9901
-
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
- HY-P99795
-
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
-
- HY-P991143
-
|
Claudin
|
Cancer
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
-
- HY-P991195
-
|
TNF Receptor
|
Cancer
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P99102
-
10-1074
|
HIV
|
Infection
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
-
- HY-P991145
-
|
SLC39 (Zinc Transporter)
|
Cancer
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
- HY-P991137
-
|
Ser/Thr Protease
|
Metabolic Disease
|
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
|
-
- HY-P990912
-
-
- HY-P990014
-
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
- HY-P99007
-
BAY 1179470
|
FGFR
|
Cancer
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
-
- HY-P99936
-
LJM716
|
EGFR
|
Cancer
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
-
- HY-P990953
-
-
- HY-P990913
-
bsAb7075; REGN-7075
|
EGFR
|
Inflammation/Immunology
|
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99661
-
|
Interleukin Related
|
Cancer
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
-
- HY-P991130
-
|
Amyloid-β
|
Neurological Disease
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
-
- HY-P99197
-
CP-751871
|
IGF-1R
|
Cancer
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
-
- HY-P991125
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
-
- HY-P991192
-
|
TNF Receptor
|
Cancer
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
-
- HY-P991156
-
|
Ras
|
Inflammation/Immunology
|
Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
|
-
- HY-P991127
-
|
Complement System
|
Inflammation/Immunology
|
Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
-
- HY-P9920A
-
|
VEGFR
|
Cancer
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
-
- HY-P991061
-
SRF-114
|
CCR
|
Cancer
|
CHS-114 (SRF-114) is a fully human IgG1 antibody that targets CCR8. CHS-114 has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991057
-
|
CD47
|
Cancer
|
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991123
-
|
Adenylate Cyclase
|
Inflammation/Immunology
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
-
- HY-P9927
-
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
-
- HY-P99415
-
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
- HY-P99770
-
514-G3
|
Bacterial
|
Infection
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
-
- HY-P991128
-
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
|
-
- HY-P99710
-
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
-
- HY-P99807
-
BCD-100
|
PD-1/PD-L1
|
Cancer
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
- HY-P990094
-
CSL311
|
c-Fms
|
Inflammation/Immunology
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
-
- HY-P99643
-
UCB6114
|
Dan family
|
Cancer
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
- HY-P99294
-
AMG 479; Human Anti-IGF1R Recombinant Antibody
|
IGF-1R
|
Cancer
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
-
- HY-P99846
-
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
-
- HY-P991161
-
|
Complement System
|
Inflammation/Immunology
|
Tanruprubart is a monoclonal antibody targeting human complement C1q. Tanruprubart specifically binds to complement C1q, inhibiting the initiation of the classical complement activation pathway and exerting immunosuppressive activity. Tanruprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
-
- HY-P991138
-
|
Interleukin Related
|
Inflammation/Immunology
|
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
|
-
- HY-P99056
-
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
-
- HY-P99786
-
REGN3918
|
Complement System
|
Metabolic Disease
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
-
- HY-P99322
-
LFG316; Anti-Human C5 Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
-
- HY-P99110
-
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
-
- HY-P991141
-
|
VEGFR
|
Cancer
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
-
- HY-P99114
-
|
PD-1/PD-L1
|
Cancer
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
-
- HY-P99519
-
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
-
- HY-P991134
-
|
IGF-1R
|
Inflammation/Immunology
|
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
|
-
- HY-P99450
-
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
- HY-P99556
-
AZD8895
|
SARS-CoV
|
Infection
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
-
- HY-P99376
-
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-P9931
-
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-P991114
-
|
FLT3
|
Inflammation/Immunology
|
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
|
-
- HY-P99020
-
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
-
- HY-P99220
-
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
-
- HY-P991069
-
|
HIV
|
Infection
|
VRC-01 is a fully human IgG1 antibody that targets envelope glycoprotein gp120 Protein. VRC-01 blocks viral entry by partially mimicking the interaction of the CD4 receptor with HIV-1 gp120 envelope glycoprotein. The isotype control for VRC-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99669
-
MDX-060
|
TNF Receptor
|
Cancer
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
-
- HY-P9919
-
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
-
- HY-P99218
-
Sch 717454; 19D12
|
IGF-1R
|
Cancer
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
|
-
- HY-P99541
-
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
-
- HY-P99836
-
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
-
- HY-P99191
-
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-P99299
-
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
-
- HY-P99486
-
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
-
- HY-P990015
-
VIR-3434
|
HBV
|
Infection
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P9958
-
AMG-162
|
NF-κB
Caspase
Apoptosis
RANKL/RANK
|
Endocrinology
Cancer
|
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
-
- HY-P991129
-
|
Interleukin Related
|
Inflammation/Immunology
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991144
-
|
Interleukin Related
|
Inflammation/Immunology
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
-
- HY-P990928
-
|
CD3
|
Inflammation/Immunology
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
-
- HY-P99688
-
AL001
|
Neurotensin Receptor
|
Cancer
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
-
- HY-P99913
-
|
c-Fms
|
Inflammation/Immunology
Cancer
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
-
- HY-P991142
-
|
MHC
|
Inflammation/Immunology
Cancer
|
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
|
-
- HY-P99637
-
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
-
- HY-P991201
-
|
Interleukin Related
|
Inflammation/Immunology
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991068
-
|
Transmembrane Glycoprotein
|
Cancer
|
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99342
-
REGN10987
|
SARS-CoV
|
Infection
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
-
- HY-P9961
-
|
CD20
|
Cancer
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
|
-
- HY-P9958A
-
|
RANKL/RANK
Apoptosis
NF-κB
|
Neurological Disease
Endocrinology
Cancer
|
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
-
- HY-P991070
-
|
TNF Receptor
|
Cancer
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991073
-
|
Amyloid-β
|
Neurological Disease
|
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99344
-
Anti-Human SARS-CoV-2
|
SARS-CoV
|
Infection
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
-
- HY-P99268
-
SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
-
- HY-P990078
-
LY3372993
|
Amyloid-β
|
Neurological Disease
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
|
-
- HY-P99203
-
|
PD-1/PD-L1
|
Cancer
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
-
- HY-P991173
-
|
Notch
|
Cancer
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99552
-
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
-
- HY-P990932
-
BI 764532; OBT 620
|
CD3
|
Inflammation/Immunology
|
HY-P990932 is an CD3E/HEK-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .
|
-
- HY-P99155
-
|
EGFR
|
Cancer
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
-
- HY-P99772
-
L19TNF
|
TNF Receptor
|
Cancer
|
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
|
-
- HY-P991054
-
|
Influenza Virus
|
Infection
|
CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC50s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99479
-
L19-IL2
|
Interleukin Related
|
Cancer
|
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity .
|
-
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-P99190
-
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
-
- HY-163480
-
|
CXCR
|
Inflammation/Immunology
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P9919A
-
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
-
- HY-P99810
-
AVTX-002; AEVI 002; SAR 252067
|
SARS-CoV
|
Cardiovascular Disease
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
-
- HY-P99518
-
BMS 986089; RG 6206; RO 7239361; BHV2000
|
TGF-beta/Smad
|
Others
|
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
|
-
- HY-P99055
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
- HY-P991146
-
|
Interleukin Related
|
Inflammation/Immunology
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99109
-
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
- HY-P99925
-
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
|
-
- HY-P990090
-
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
-
- HY-145644
-
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-P99189
-
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
-
- HY-P99551
-
KBSA301; AR-301
|
Antibiotic
|
Infection
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
-
- HY-P99583
-
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
-
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
- HY-P99833
-
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
|
-
- HY-P99392
-
|
CD3
|
Cancer
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
-
- HY-P99111
-
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
- HY-P99410
-
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
-
- HY-P99165
-
|
IGF-1R
TSH Receptor
|
Endocrinology
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
-
- HY-P99341
-
REGN10933
|
SARS-CoV
|
Infection
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
-
- HY-P99509
-
-
- HY-P991200
-
|
Claudin
HCV
|
Infection
|
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
|
-
- HY-P9930
-
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
-
- HY-P99620
-
CT-P22; CT120
|
Influenza Virus
|
Infection
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
- HY-P99759
-
IL-15N72D
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
|
-
- HY-P99324
-
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
- HY-P990302
-
|
nAChR
|
Others
|
Anti-Human/Rat/Fish AChR Antibody (Mab35) is a rat-derived IgG1 type antibody inhibitor, targeting to human/rat/Fish AChR.
|
-
- HY-P990833
-
|
Mesothelin
|
Others
|
Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
|
-
- HY-P9928
-
REGN 727; SAR 236553
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
|
-
- HY-P99359
-
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
-
- HY-P990149
-
|
Tyrosinase
|
Others
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human TYRP1.
|
-
- HY-P990238
-
|
EGFR
|
Others
|
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to human/rat HER2.
|
-
- HY-P990138
-
|
CD20
|
Others
|
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to monkey/human CD20.
|
-
- HY-NP189
-
Human IgG
|
Bacterial
|
Infection
Inflammation/Immunology
|
Human Immunoglobulin G (Human IgG) is an immunoglobulin that plays a protective role in humoral immunity by producing antibody responses against specific pathogens (such as Bacteroides forsythus and Prevotella intermedia). Human Immunoglobulin G (Human IgG) can also serve as an antibody standard for quantitative analysis in enzyme-linked immunosorbent assays (ELISA). Human Immunoglobulin G antibody levels can be used for research on rheumatoid arthritis (RA) and periodontal disease .
|
-
- HY-P991198
-
|
Tim3
|
Cancer
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
- HY-P990189
-
|
MHC
|
Others
|
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MHC class II.
|
-
- HY-P990251
-
|
MMP
|
Others
|
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.
|
-
- HY-P990207
-
|
Integrin
|
Others
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.
|
-
- HY-P991042
-
|
IGF-1R
|
Cancer
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
-
- HY-P99444
-
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
- HY-P99273
-
|
TNF Receptor
|
Cancer
|
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
|
-
- HY-P990132
-
|
CD47
|
Others
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
|
-
- HY-P990805
-
|
HSP
|
Others
|
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b kappa in vivo mouse antibody, targeting to GRP78. The recommend isotype control of Anti-Human/Mouse GRP78 Antibody (C38): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P9928A
-
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
|
-
- HY-P99304
-
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
|
Cancer
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
-
- HY-P990236
-
|
CD28
|
Others
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
|
-
- HY-P990196
-
|
P-glycoprotein
|
Others
|
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MDR-1/CD243.
|
-
- HY-P990133
-
|
TNF Receptor
|
Others
|
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154.
|
-
- HY-P990169
-
|
PD-1/PD-L1
|
Others
|
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can be used in WB and FC experiments in the context of human and mouse.
|
-
- HY-NP191
-
Human IgM
|
Complement System
|
Inflammation/Immunology
|
Human Immunoglobulin M (Human IgM) is an antibody secreted by the adaptive immune system in response to a foreign antigen. Human Immunoglobulin M is the main class of immunoglobulin that is secreted into the circulation, in the early stages of a primary antibody response. Human Immunoglobulin M is a pentamer of five IgG equivalents, with 10 Fab fragments and therefore 10 antigen-binding sites. Human Immunoglobulin M is an activator of complement .
|
-
- HY-164954
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).
|
-
- HY-P990173
-
|
PD-1/PD-L1
|
Others
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.
|
-
- HY-P99453
-
|
ADC Antibody
|
Cancer
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
- HY-P990301
-
|
Amyloid-β
|
Others
|
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b, λ type antibody inhibitor, targeting to Amyloid-beta.
|
-
- HY-P99017
-
-
- HY-P990297
-
|
CCR
|
Others
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse/rat/human CCL2/MCP-1.
|
-
- HY-P9977
-
JNJ-61186372
|
EGFR
|
Cancer
|
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
-
- HY-P990107
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an anti-mouse/human/rat/monkey/hamster/canine/bovine IgG antibody inhibitor of TGF-β . The recommend isotype control of Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P9917
-
Anti-Human IL6R, Humanized Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
-
- HY-P99785
-
HLX20
|
PD-1/PD-L1
|
Cancer
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
- HY-P990847
-
|
E-Selectin
|
Others
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-164153
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-P990850
-
|
c-Myc
|
Others
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990865
-
|
CD28
|
Others
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P99526
-
-
- HY-P990873
-
|
DNA/RNA Synthesis
|
Others
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990840
-
|
Glycoprotein VI
|
Others
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990870
-
|
CD19
|
Others
|
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990839
-
|
IFNAR
|
Others
|
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to human IFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990842
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P9998
-
UB421
|
HIV
|
Cancer
|
Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
-
- HY-P990859
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
-
- HY-P990843
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to human Glycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990856
-
|
Transferrin Receptor
|
Others
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P99264
-
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
- HY-P99335
-
Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
-
- HY-P990604
-
IMGC-936 antibody
|
MMP
|
Inflammation/Immunology
|
Anti-ADAM9 Antibody (MGA021) (IMGC-936 antibody) is a humanized antibody expressed in CHO cells that targets ADAM9. Anti-ADAM9 Antibody (MGA021) is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.62 kDa. The isotype control for Anti-ADAM9 Antibody (MGA021) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990356
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990836
-
|
Interleukin Related
|
Others
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990827
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990868
-
|
CD2
|
Others
|
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990832
-
|
MHC
|
Others
|
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990861
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-164152
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164152A
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P99332
-
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P99328
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
- HY-P990855
-
|
Integrin
|
Others
|
Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990734
-
-
- HY-P990746
-
-
- HY-P990749
-
-
- HY-147164
-
|
ADC Linker
|
Cancer
|
MC-Gly-Gly-Phe-Gly-PAB-PNP is a linker for synthesis anti-human EGFR antibody agent conjugate .
|
-
- HY-P99211
-
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
-
- HY-P99397
-
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
-
- HY-P9804
-
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
- HY-P990851
-
|
c-Kit
|
Others
|
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human c-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990852
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990328
-
XT-M4
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990858
-
|
CD47
|
Others
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990862
-
|
CD3
|
Others
|
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990867
-
|
Insulin Receptor
|
Others
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P9981
-
XmAb5574; MOR00208; Tafasitamab-cxix
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
- HY-P990013
-
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
-
- HY-P990054
-
|
CD20
|
Cancer
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
-
- HY-P990753
-
-
- HY-P99616
-
MOR-202
|
CD38
|
Cancer
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
-
- HY-P990781
-
SM03
|
CD22
|
Inflammation/Immunology
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990686
-
|
TNF Receptor
|
Inflammation/Immunology
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990697
-
ARX-788
|
EGFR
|
Inflammation/Immunology
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990729
-
|
CD19
|
Inflammation/Immunology
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990764
-
|
Integrin
|
Inflammation/Immunology
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990747
-
|
CD38
|
Inflammation/Immunology
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990739
-
|
CTLA-4
|
Inflammation/Immunology
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991166
-
|
Mucin
|
Others
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990767
-
-
- HY-P990712
-
|
Insulin Receptor
|
Inflammation/Immunology
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990775
-
|
CTLA-4
|
Inflammation/Immunology
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99280
-
Anti-Human IL17A/IL-17F Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
-
- HY-P99010A
-
|
Interleukin Related
FGFR
|
Cancer
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
-
- HY-P990837
-
|
Interleukin Related
|
Others
|
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
-
- HY-P991163
-
|
CD3
Claudin
|
Cancer
|
Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers .
|
-
- HY-P991169
-
|
Factor Xa
|
Cardiovascular Disease
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990758
-
|
VEGFR
|
Inflammation/Immunology
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990737
-
|
CXCR
|
Inflammation/Immunology
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99034
-
-
- HY-P990713
-
-
- HY-P990773
-
|
CD28
|
Inflammation/Immunology
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P9985
-
RC48
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
|
-
- HY-P99014
-
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
-
- HY-P9914
-
Anti-Human C5, Humanized Antibody
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
-
- HY-P990771
-
|
CD73
|
Inflammation/Immunology
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990704
-
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990755
-
|
EGFR
|
Inflammation/Immunology
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99356
-
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
-
- HY-P5276
-
|
PD-1/PD-L1
|
Cancer
|
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production .
|
-
- HY-P99393
-
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
-
- HY-P99038
-
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
-
- HY-P990726
-
|
TNF Receptor
|
Inflammation/Immunology
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990702
-
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990854
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990831
-
|
Mucin
|
Others
|
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to human MUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
|
-
- HY-P990541
-
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-141607
-
-
- HY-P99515
-
-
- HY-P99160
-
|
Transmembrane Glycoprotein
|
Cancer
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
-
- HY-P99638
-
-
- HY-P990690
-
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990761
-
-
- HY-P990700
-
RO-7247669
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990694
-
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990701
-
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99234
-
|
Interleukin Related
ADC Antibody
|
Cancer
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P99013
-
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
- HY-P990829
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human NKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-145626
-
BA302
|
ADC Antibody
|
Cancer
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
-
- HY-P99187
-
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
-
- HY-P9950
-
Olizumab; rhuMab-E25
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .
|
-
- HY-P990751
-
-
- HY-P99656
-
MCDS0593A
|
ADC Antibody
|
Cancer
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P99813
-
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-141606
-
BAY 94-9343
|
Microtubule/Tubulin
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
|
-
- HY-141604
-
-
- HY-P99354
-
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
-
- HY-P3203
-
-
- HY-P99612
-
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-P990871
-
|
Integrin
|
Others
|
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990844
-
|
Complement System
|
Others
|
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990857
-
|
Integrin
|
Others
|
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990752
-
REGN-5678
|
CD28
|
Inflammation/Immunology
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P3203A
-
|
TNF Receptor
|
Inflammation/Immunology
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-108852
-
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
- HY-P99313
-
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
- HY-NP116
-
Human Type I collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type I collagen, from human placenta (Human Type I collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP118
-
Human Type III collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type III collagen, from human placenta (Human Type III collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-108905
-
Human IGF-I; FK 780
|
IGF-1R
|
Metabolic Disease
|
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
|
-
- HY-P99796
-
ATN-103
|
TNF Receptor
|
Inflammation/Immunology
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
-
- HY-P990691
-
-
- HY-P99909
-
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990692
-
|
CD3
|
Inflammation/Immunology
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
39 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-P99209
-
MEDI-524
|
RSV
|
Infection
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
- HY-P991132
-
|
VEGFR
|
Cardiovascular Disease
Cancer
|
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
|
-
- HY-P99465
-
-
- HY-P99832
-
c13C6-FR1
|
Filovirus
|
Infection
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
-
- HY-NP121
-
Human Type XI collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type XI collagen, from human sternal cartilage (Human Type XI collagen, immunization grade) is an immune grade collagen derived from human sternal cartilage, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP120
-
Human Placenta Type V collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type V collagen, from human placenta (Human Placenta Type V collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP119
-
Human Amnion Type V collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type V collagen, from human amnion (Human Amnion Type V collagen, immunization grade) is an immune grade collagen derived from human amnion, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP117
-
Human Type II collagen, immunization grade
|
MMP
|
Inflammation/Immunology
|
Highly purified Type II collagen, from human sternal cartilage (Human Type II collagen, immunization grade) is an immune grade collagen derived from human sternal cartilage, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-P99530
-
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
-
- HY-P99151
-
|
ADC Antibody
TNF Receptor
|
Cancer
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
-
- HY-P99302
-
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
|
-
- HY-P990526
-
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990933
-
-
- HY-P990906
-
-
- HY-P99337
-
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99857
-
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-P990957
-
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9979
-
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
- HY-P990929
-
|
Mesothelin
|
Inflammation/Immunology
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99607
-
IDEC-151
|
HIV
|
Inflammation/Immunology
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
-
- HY-P9S0008
-
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
-
- HY-P990995
-
|
Tau Protein
|
Inflammation/Immunology
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9966
-
MGA271
|
CD276/B7-H3
|
Cancer
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
- HY-P990027
-
|
ADC Antibody
|
Cancer
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
-
- HY-118870
-
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
γ-Globulins from human blood are a class of proteins in the blood. γ-Globulin is a protein fraction of blood serum containing many antibodies that protect against bacterial and viral infectious diseases. γ-Globulins from human blood is used for common variable immunodeficiency
|
-
- HY-P991154
-
|
VEGFR
PD-1/PD-L1
|
Cancer
|
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascular endothelial growth factor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .
|
-
- HY-164669
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
|
-
- HY-152963
-
|
Antibody-Drug Conjugates (ADCs)
|
Inflammation/Immunology
Cancer
|
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
|
-
- HY-P990060
-
Mim8
|
Factor Xa
|
Cardiovascular Disease
|
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
|
-
- HY-153907
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
- HY-P99736
-
BI-754111
|
LAG-3
|
Cancer
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
-
- HY-P990363
-
PTA001_A4
|
Cadherin
|
Inflammation/Immunology
|
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99550
-
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-P991150
-
|
Interleukin Related
|
Inflammation/Immunology
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P99442
-
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
- HY-P99895
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
- HY-P990961
-
|
VEGFR
PD-1/PD-L1
|
Inflammation/Immunology
|
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99797
-
JR-141
|
Transferrin Receptor
|
Neurological Disease
|
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
|
-
- HY-P99662
-
MLN0264; TAK-264
|
Antibody-Drug Conjugates (ADCs)
Guanylate Cyclase
Apoptosis
|
Cancer
|
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
|
-
- HY-164668
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).
|
-
- HY-P991168
-
|
Amyloid-β
CCR
|
Neurological Disease
Inflammation/Immunology
|
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
|
-
- HY-145622
-
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
|
TAM Receptor
|
Cancer
|
Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research .
|
-
- HY-P10628
-
|
Amyloid-β
|
Neurological Disease
|
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
|
-
- HY-P990993
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990978
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990904
-
|
CCR
|
Inflammation/Immunology
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991038
-
|
CD28
|
Inflammation/Immunology
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990919
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990960
-
-
- HY-P991014
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990914
-
|
CCR
|
Inflammation/Immunology
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99365
-
ALXN1210
|
Complement System
|
Metabolic Disease
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
- HY-145675A
-
|
Interleukin Related
|
Inflammation/Immunology
|
(R)-TCB2 is the R-enantiomer of TCB2. TCB2 is a potent anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity .
|
-
- HY-P990945
-
|
CTLA-4
|
Inflammation/Immunology
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990908
-
|
CCR
|
Inflammation/Immunology
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99196
-
|
c-Met/HGFR
|
Cancer
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
-
- HY-P991162
-
|
Interleukin Related
|
Inflammation/Immunology
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P990930
-
|
CD22
|
Inflammation/Immunology
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990949
-
|
c-Met/HGFR
|
Inflammation/Immunology
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-171191
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
c-Met/HGFR
|
Cancer
|
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
|
-
- HY-P99252
-
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
- HY-138298A
-
DS-8201; DS-8201a
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-P99325
-
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
|
-
- HY-P99668
-
|
PD-1/PD-L1
|
Cancer
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P990994
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991203
-
|
Guanylate Cyclase
|
Cancer
|
PF-07062119 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits GUCY2C, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P990925
-
|
CD3
|
Inflammation/Immunology
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990962
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99222
-
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
-
- HY-P99648
-
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
-
- HY-P991000
-
-
- HY-P99115
-
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
-
- HY-164992
-
MRG002; Trastuzumab MMAE
|
Antibody-Drug Conjugates (ADCs)
EGFR
Microtubule/Tubulin
|
Cancer
|
Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer .
|
-
- HY-138298
-
DS-8201 (solution); DS-8201a (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-P99945
-
-
- HY-P10458
-
Human/rat 5-LO (130-149)
|
Lipoxygenase
|
Others
|
5-Lipoxygenase blocking peptide (Human/rat 5-LO 130-149) is a specific sequence fragment of 5-lipoxygenase (5-LOX), which can be utilized to prepare an antibody against 5-LOX .
|
-
- HY-P99652
-
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
-
- HY-P9801
-
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P4025
-
|
HIV
|
Others
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
- HY-P9934
-
C7E3
|
Integrin
|
Cardiovascular Disease
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
-
- HY-P9807
-
SARS-CR3022; SARS-CoV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
- HY-P99346
-
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99306
-
DS 1024
|
EGFR
|
Cancer
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
- HY-P991155
-
|
CD3
TNF Receptor
|
Cancer
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
-
- HY-P991063
-
BNT-313
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99437
-
KN-026
|
EGFR
|
Cancer
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
|
-
- HY-172820
-
DP303c
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .
|
-
- HY-P991019
-
-
- HY-P99768
-
TTAC-0001
|
VEGFR
|
Cancer
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
-
- HY-P991147
-
|
PD-1/PD-L1
|
Cancer
|
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
|
-
- HY-P990910
-
-
- HY-P990955
-
|
CD3
|
Inflammation/Immunology
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990983
-
-
- HY-P99399
-
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P9991
-
TST001
|
Gap Junction Protein
|
Cancer
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
- HY-P991050
-
AK-1967
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99902
-
FAP-IL2v
|
Interleukin Related
|
Cancer
|
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
|
-
- HY-P99385
-
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
- HY-P9954
-
|
CD3
|
Cancer
|
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
|
-
- HY-P990899
-
|
CD47
|
Inflammation/Immunology
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P991024
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-160180
-
-
- HY-P991023
-
|
CD47
|
Inflammation/Immunology
|
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99776
-
XmAb-13676
|
CD20
CD3
|
Cancer
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
-
- HY-P99336
-
BI-RR 0001; Anti-Human IL6 Recombinant Antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
-
- HY-160178
-
-
- HY-P99333
-
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
- HY-P991149
-
|
TNF Receptor
|
Cancer
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
-
- HY-P99595
-
AGS15E; ASG-15ME; 1vcMMAE
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
|
-
- HY-P991172
-
|
CD3
Transmembrane Glycoprotein
|
Cancer
|
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
|
-
- HY-153360
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
- HY-P99371
-
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P99756
-
MEDI8897
|
RSV
|
Infection
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
- HY-P99680
-
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
- HY-P991062
-
Gensci-059
|
CD47
|
Cancer
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99417
-
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
-
- HY-P99162
-
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P990571
-
|
CD19
|
Inflammation/Immunology
|
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99378
-
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
-
- HY-P9803
-
SARS-80R; SARS Antibody-80R
|
SARS-CoV
|
Infection
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
- HY-P99282
-
VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A
|
Apoptosis
|
Cancer
|
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
|
-
- HY-P991051
-
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P5201S1
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-P5201S
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-P990969
-
|
CD3
|
Inflammation/Immunology
|
HY-P990969 is an CD3E/CD4-targeting IgG1?λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99361
-
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P990631
-
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P99345
-
TSR-042
|
PD-1/PD-L1
|
Cancer
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
- HY-P99618
-
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
-
- HY-P990673
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991052
-
|
TNF Receptor
|
Cancer
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990651
-
|
TREM receptor
|
Inflammation/Immunology
|
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991066
-
|
nAChR
|
Neurological Disease
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-164202
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .
|
-
- HY-P99349
-
Loncastuximab tesirine-lpyl; ADCT-402
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
|
-
- HY-P99293
-
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
|
Cancer
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
-
- HY-148420
-
|
STING
|
Inflammation/Immunology
|
CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes .
|
-
- HY-P990782
-
|
Aminoacyl-tRNA Synthetase
|
Inflammation/Immunology
|
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
|
-
- HY-P991151
-
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P990662
-
|
Interleukin Related
|
Inflammation/Immunology
|
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P9806
-
MERS-D12; MERS Antibody-D12
|
SARS-CoV
|
Infection
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
- HY-P990642
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99493
-
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-153084A
-
|
CD19
|
Cancer
|
CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
-
- HY-P9984
-
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
-
- HY-P99163
-
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
-
- HY-P990318
-
|
VEGFR
|
Inflammation/Immunology
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990093
-
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
-
- HY-P990017
-
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
-
- HY-P990594
-
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990661
-
|
c-Met/HGFR
|
Inflammation/Immunology
|
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99962
-
BGB-A425
|
Mucin
|
Cancer
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
- HY-P990678
-
|
TNF Receptor
|
Inflammation/Immunology
|
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990312
-
|
Interleukin Related
|
Inflammation/Immunology
|
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-164957
-
|
Antibody-Drug Conjugates (ADCs)
Integrin
|
Cancer
|
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
|
-
- HY-P990595
-
|
Amyloid-β
|
Inflammation/Immunology
|
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990314
-
|
EGFR
|
Inflammation/Immunology
|
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 74.5 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990719
-
XmAb24306
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
|
-
- HY-P990602
-
|
Interleukin Related
|
Inflammation/Immunology
|
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99464
-
IMMU-LL 2
|
CD22
|
Cancer
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
-
- HY-P990008
-
Atrosab
1 Publications Verification
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9949
-
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
- HY-P99492
-
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P990667
-
|
Integrin
|
Inflammation/Immunology
|
STX-100 is a humanized antibody expressed in CHO cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99248
-
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
- HY-120471
-
|
PI3K
|
Inflammation/Immunology
|
AM-0687 is a selective inhibitor for PI3Kδ with an IC50 of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC50=0.8 nM) and the phosphorylation of AKT (IC50=0.7 nM), and exhibits anti-inflammatory efficacy .
|
-
- HY-P3560
-
TV 4710
|
Apoptosis
|
Inflammation/Immunology
|
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
|
-
- HY-P990573
-
RG-7636
|
Endothelin Receptor
|
Inflammation/Immunology
|
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99575
-
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
- HY-P9999
-
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
-
- HY-P99737
-
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P99008
-
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
|
-
- HY-P990592
-
E-6071; HGS-1035
|
CCR
|
Inflammation/Immunology
|
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990613
-
CBA-1205
|
Notch
|
Inflammation/Immunology
|
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991067
-
KP-104
|
Complement System
|
Inflammation/Immunology
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
-
- HY-P99803
-
VAL-1221
|
Glycosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-P990612
-
AML-01
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991080
-
ASG-5ME Antibody; AGS-5M2
|
ADC Antibody
|
Cancer
|
Anti-SLC44A4 Antibody (ASG-5ME Antibody) is a SLC44A4 targeting antibody that can be used for synthesis of ADC ASG-5ME .
|
-
- HY-P99103
-
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
-
- HY-145643
-
ZRC3308-B10
|
SARS-CoV
|
Infection
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P99709
-
LY3300054
|
PD-1/PD-L1
|
Cancer
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
-
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
-
- HY-P99352
-
Anti-MSLN Antibody
|
Mesothelin
ADC Antibody
|
Cancer
|
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
|
-
- HY-P9926
-
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
-
- HY-P99630
-
MM-302
|
EGFR
|
Cancer
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
-
- HY-P99383
-
REMD-477; AMG-477
|
GCGR
|
Metabolic Disease
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
|
-
- HY-P990086
-
|
Interleukin Related
|
Cancer
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
-
- HY-P990067
-
ATOR-1017
|
TNF Receptor
|
Cancer
|
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
|
-
- HY-145641
-
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
-
- HY-P99653A
-
|
TNF Receptor
Apoptosis
|
Cancer
|
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
|
-
- HY-P990708
-
-
- HY-P991113
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
-
- HY-P99152
-
|
CD3
|
Inflammation/Immunology
Cancer
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
-
- HY-P99775
-
ART621; CEP-37247; PN0621
|
TNF Receptor
|
Inflammation/Immunology
|
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
|
-
- HY-P990896
-
|
ADC Antibody
|
Cancer
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
-
- HY-P990085
-
|
Tim3
|
Infection
|
Verzistobart is an IgG1κ antibody targeting the hepatitis A virus cellular receptor HAVCR2.
|
-
- HY-P99565
-
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
-
- HY-P99853
-
CR6261
|
Influenza Virus
|
Infection
|
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
|
-
- HY-P99804
-
MK1654
|
RSV
|
Infection
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
|
-
- HY-P991157
-
|
RSV
|
Infection
|
Retavibart is a human respiratory syncytial virus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
|
-
- HY-P99871
-
AK102
|
PCSK9
|
Others
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .
|
-
- HY-P9980A
-
|
ADC Antibody
TNF Receptor
|
Cancer
|
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
|
-
- HY-P991193
-
|
MMP
|
|
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
|
-
- HY-P99499
-
JNJ 63723283; JNJ 3283
|
PD-1/PD-L1
Interleukin Related
TNF Receptor
|
Cancer
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
|
-
- HY-P991180
-
|
TNF Receptor
|
Cancer
|
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
|
-
- HY-P99777
-
TTI-621
|
CD47
|
Cancer
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
-
- HY-P99459
-
BG 9924; TT-47
|
TNF Receptor
|
Inflammation/Immunology
|
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
|
-
- HY-P99543
-
OPRX-106; PRX-106; TNFR-Fc
|
TNF Receptor
|
Cancer
|
Tulinercept (OPRX-106) is a recombinant TNF receptor fusion protein fused to an IgG1 Fc domain .
|
-
- HY-P99016
-
|
ADC Antibody
Nectin-4
|
Cancer
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
-
- HY-P99799
-
CX-072
|
PD-1/PD-L1
|
Cancer
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
-
- HY-P990006
-
TEV-48574
|
TNF Receptor
|
Inflammation/Immunology
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
- HY-P99621
-
NPC-21; EV2038
|
CMV
|
Infection
|
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
|
-
- HY-P99722
-
REGN3470-3471-3479
|
Filovirus
|
Infection
|
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
|
-
- HY-P99723
-
BCD-135
|
PD-1/PD-L1
|
Cancer
|
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
|
-
- HY-P990706
-
ALPN-303
|
TNF Receptor
|
Inflammation/Immunology
|
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
|
-
- HY-P99414
-
AMG 557
|
CD28
|
Inflammation/Immunology
|
Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors .
|
-
- HY-P99670
-
-
- HY-P991190
-
|
TGF-beta/Smad
|
|
AV-380 is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
-
- HY-P99844
-
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Cancer
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99386
-
MNRP-1685A
|
Complement System
EGFR
PDGFR
p38 MAPK
|
Cancer
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
|
-
- HY-P99458
-
CG 10639
|
c-Fms
|
Cancer
|
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
|
-
- HY-P99887
-
JTX-4014
|
PD-1/PD-L1
|
Cancer
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor .
|
-
- HY-P99529
-
BAX1810; TAK-752
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
|
-
- HY-P99037
-
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
- HY-P99667
-
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
- HY-P99106
-
-
- HY-P99031
-
CAM 3001
|
c-Fms
|
Cardiovascular Disease
Inflammation/Immunology
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
|
-
- HY-P99794
-
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
-
- HY-P99343
-
REGN3470
|
Filovirus
|
Infection
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
|
-
- HY-P99478
-
|
IFNAR
|
Inflammation/Immunology
|
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
|
-
- HY-P99720
-
ACE-536; luspatercept–aamt
|
TGF-beta/Smad
|
Metabolic Disease
Cancer
|
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
|
-
- HY-P99441
-
SRK-015
|
TGF-beta/Smad
|
Neurological Disease
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
|
-
- HY-P99491
-
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
-
- HY-P991194
-
|
TNF Receptor
|
Cancer
|
HFB-200301 is an IgG1 antibody targeting tumor necrosis factor receptor 2 (TNFR2). HFB-200301 promotes the activation of TNFR2, thereby activating relevant signaling pathways, such as activating RelA and cRel-containing NF-κB dimers through the classical NF-κB pathway, affecting cell metabolism and gene expression in the presence of sTNF. HFB-200301 is promising for research of cancers .
|
-
- HY-P99718
-
BAY 1112623
|
ADC Antibody
|
Cancer
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
-
- HY-P9986
-
MTIG-7192A; RG-6058
|
CD28
|
Inflammation/Immunology
Cancer
|
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) .
|
-
- HY-P990703
-
-
- HY-145642
-
ZRC3308-A7
|
SARS-CoV
|
Infection
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P99725
-
-
- HY-P990786
-
|
FLT3
ADC Antibody
|
Cancer
|
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
|
-
- HY-P99219
-
MEDI-545; MDX 1103
|
IFNAR
|
Inflammation/Immunology
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
|
-
- HY-P99624
-
CR4098
|
RABV
|
Infection
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
|
-
- HY-P99048A
-
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P99930
-
|
FGFR
|
Metabolic Disease
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-P99198
-
-
- HY-P99608
-
|
HBV
|
Infection
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
-
- HY-P99433
-
U 85855
|
HIV
|
Infection
|
Alvircept sudotox is a recombinant CD4 derived from Pneumonas aeruginosa exotoxin A. Alvircept sudotox can be used in the research of HIV infections .
|
-
- HY-P990052
-
MAD-0004J08
|
SARS-CoV
|
Infection
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
-
- HY-P9952
-
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .
|
-
- HY-P990959
-
-
- HY-P99487
-
BR 3FC
|
ADC Antibody
|
Inflammation/Immunology
|
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
|
-
- HY-P99445
-
APG101; CAN008
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
|
-
- HY-P99402
-
REGN 2176
|
PDGFR
|
Metabolic Disease
|
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
|
-
- HY-P99698
-
LDP
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
|
-
- HY-P99420
-
ALPN-101
|
CD28
|
Inflammation/Immunology
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
-
- HY-P99924
-
|
GHR
|
Others
|
Efpegsomatropin is a human growth hormone-Fc conjugate peptide. Efpegsomatropin can be used for various biochemical studies.
|
-
- HY-P99467
-
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
-
- HY-P99009
-
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
- HY-P991167
-
|
Bacterial
|
Infection
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
-
- HY-P99516
-
HLX-06
|
VEGFR
|
Cancer
|
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
|
-
- HY-P99692
-
p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1
|
TNF Receptor
|
Inflammation/Immunology
|
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
|
-
- HY-P99553
-
42-89-glycoprotein; WAY164339; pMT21:PL85
|
P-selectin
|
Others
|
Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
|
-
- HY-P99729
-
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
-
- HY-P991148
-
|
PD-1/PD-L1
|
Cancer
|
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
|
-
- HY-P990037
-
|
CD38
|
Cancer
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
-
- HY-P99053
-
-
- HY-P991181
-
-
- HY-P99750
-
CT-P23
|
Influenza Virus
|
Infection
|
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
|
-
- HY-P99223
-
MEDI-575
|
PDGFR
|
Cancer
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99244
-
ILV 094
|
Interleukin Related
|
Inflammation/Immunology
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99226
-
MEDI7734; VIB7734
|
SARS-CoV
|
Cancer
|
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
|
-
- HY-P991179
-
|
TNF Receptor
|
Cancer
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
- HY-P99360
-
Anti-AXL/UFO Reference Antibody (enapotamab)
|
TAM Receptor
|
Cancer
|
Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .
|
-
- HY-P990707
-
TTI-622; PF-07901801
|
CD47
|
Inflammation/Immunology
|
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
|
-
- HY-P99536
-
SL-401
|
Interleukin Related
|
Cancer
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
-
- HY-P991178
-
|
TNF Receptor
|
Cancer
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
- HY-P99568
-
RC18
|
TNF Receptor
|
Inflammation/Immunology
|
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .
|
-
- HY-P99823
-
TA-46; sFGFR3
|
FGFR
|
Others
|
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
|
-
- HY-P991153
-
|
Virus Protease
|
Infection
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
-
- HY-P99022
-
|
Amyloid-β
|
Neurological Disease
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
- HY-P99217
-
AMG 102
|
c-Met/HGFR
|
Cancer
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
-
- HY-P99388
-
REGN-1033
|
TGF-beta/Smad
|
Metabolic Disease
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
|
-
- HY-P990111
-
-
- HY-P99527
-
ACC-001; PF 05236806
|
Amyloid-β
|
Neurological Disease
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99440
-
CSL-324
|
c-Fms
JAK
STAT
|
Inflammation/Immunology
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
|
-
- HY-P99966
-
|
RANKL/RANK
|
Cancer
|
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .
|
-
- HY-P99782
-
|
TNF Receptor
|
Inflammation/Immunology
|
Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .
|
-
- HY-P99208
-
IPH2102
|
Transmembrane Glycoprotein
|
Cancer
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
|
-
- HY-P99645
-
-
- HY-P99578
-
HL036337; HBM9036
|
TNF Receptor
|
Inflammation/Immunology
|
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
|
-
- HY-P99048
-
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P990079
-
|
CD28
|
Inflammation/Immunology
|
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .
|
-
- HY-P99818
-
ACE-031
|
TGF-β Receptor
|
Metabolic Disease
|
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
|
-
- HY-P9991A
-
|
Gap Junction Protein
|
Cancer
|
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
- HY-P99748
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
|
-
- HY-P99940
-
ABT-122
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
|
-
- HY-P99296
-
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
EGFR
|
Cancer
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
|
-
- HY-P99233
-
HuMax-TAC
|
Interleukin Related
|
Cancer
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .
|
-
- HY-P99316
-
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
- HY-P99590
-
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
-
- HY-P99937
-
|
HIV
|
Infection
|
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
|
-
- HY-P99811
-
CR57
|
RABV
|
Infection
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
-
- HY-145629
-
|
Lipocalin Family
|
Others
|
Palsucibep pegol is a engineered human lipocalin-2 binding protein. Palsucibep pegol binds to hepcidin .
|
-
- HY-P99446
-
TACI-Ig; TACI-Fc 5
|
TNF Receptor
|
Inflammation/Immunology
|
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
|
-
- HY-P990024
-
-
- HY-P99830
-
KH902
|
VEGFR
|
Cardiovascular Disease
|
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
|
-
- HY-P99406A
-
|
EGFR
|
Cancer
|
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
|
-
- HY-P990059
-
|
CD276/B7-H3
|
Cancer
|
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
|
-
- HY-P99463
-
AVB-500; AVB-S6-500
|
TAM Receptor
|
Cancer
|
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
|
-
- HY-P99687
-
AMG 256
|
PD-1/PD-L1
|
Cancer
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
-
- HY-P99793
-
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
-
- HY-128946
-
|
Drug-Linker Conjugates for ADC
|
Inflammation/Immunology
Cancer
|
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
|
-
- HY-172107
-
|
MAP4K
Interleukin Related
|
Inflammation/Immunology
Cancer
|
HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody .
|
-
- HY-P991055
-
RG-6234; RO-7425781
|
CD3
|
Inflammation/Immunology
|
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P10056
-
Human ezrin peptide (324-337)
|
HIV
HCV
HPV
Influenza Virus
Interleukin Related
|
Infection
Inflammation/Immunology
|
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
|
-
- HY-P99941
-
|
PD-1/PD-L1
|
Cancer
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
-
- HY-P99496
-
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
- HY-P9992
-
BAY-2315497; PSMA-TTC
|
PSMA
|
Inflammation/Immunology
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
|
-
- HY-P99754
-
|
Interleukin Related
|
Inflammation/Immunology
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
-
- HY-P990688
-
-
- HY-P9996
-
LY3434172
|
PD-1/PD-L1
|
Cancer
|
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
|
-
- HY-P990073
-
REGN-5093
|
c-Met/HGFR
|
Cancer
|
Davutamig (REGN-5093) is a humanIgG4-kappa, anti-MET bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .
|
-
- HY-P99672
-
MM 141; MM-005
|
IGF-1R
EGFR
|
Cancer
|
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
|
-
- HY-P990714
-
|
CD3
|
Inflammation/Immunology
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
- HY-P99663
-
|
TNF Receptor
|
Cancer
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
-
- HY-P99965
-
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
-
- HY-P99517
-
JNJ-63898081
|
CD3
|
Cancer
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
-
- HY-P99931
-
GEN3013
|
CD3
CD20
|
Cancer
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
-
- HY-P99350
-
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
-
- HY-P99958
-
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
|
Cancer
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
-
- HY-108786
-
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
-
- HY-108801
-
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
-
- HY-108822
-
Arcalyst; IL 1 Trap; Interleukin 1 Trap
|
Interleukin Related
|
Inflammation/Immunology
|
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
|
-
- HY-P99666
-
|
IFNAR
|
Infection
Cancer
|
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
|
-
- HY-P99752
-
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
-
- HY-145633
-
OPT 302; VGX-300
|
VEGFR
|
Cardiovascular Disease
|
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
|
-
- HY-P3385
-
SCB-313
|
Drug Derivative
|
Others
|
Rilunermin alfa (SCB-313) is an active compound. Rilunermin alfa can be used for various biochemical studies .
|
-
- HY-112935
-
BAX326; Coagulation Factor IX [Recombinant]
|
Ser/Thr Protease
|
Others
|
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .
|
-
- HY-118860
-
Org 36286; MK-8962
|
Estrogen Receptor/ERR
|
Endocrinology
|
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
|
-
- HY-P99919
-
|
Interleukin Related
|
Infection
|
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
|
-
- HY-108847
-
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
-
- HY-P99769
-
SCT-800
|
Factor VIII
|
Metabolic Disease
|
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
|
-
- HY-P99845
-
MEDI 4920; VIB 4920
|
TNF Receptor
|
Others
|
Dazodalibep (MEDI 4920; VIB 4920) is a fusion protein targeting CD40LG/TNFSF5 fused to human serum albumin ALB/HSA .
|
-
- HY-P99348
-
Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b
|
Apoptosis
|
Cancer
|
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .
|
-
- HY-P99911
-
-
- HY-P99665
-
LY-3209590
|
Insulin Receptor
|
Metabolic Disease
|
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
|
-
- HY-P99735
-
|
IFNAR
|
Infection
|
Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
|
-
- HY-112998
-
|
Factor VIII
|
Others
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
-
- HY-P99974
-
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
Nab-Paclitaxel is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel (Paclitaxel: human albumin=1:9), in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel was associated with higher response rates and better tolerability, with favorable pharmacokinetic properties . (The product size below only indicate the effective content of Paclitaxel. The actual albumin quality depends on the batch. The ratio of each component in this product is Paclitaxel: albumin = 1:7-1:11.)
|
-
- HY-P99944
-
Retlirafusp alfa
|
PD-1/PD-L1
TGF-β Receptor
|
Cancer
|
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
|
-
- HY-P99696
-
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
-
- HY-P99917
-
|
STAT
|
Inflammation/Immunology
|
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
|
-
- HY-P99934
-
ABBV-621
|
Apoptosis
|
Cancer
|
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
|
-
- HY-108829
-
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-P99905
-
|
VEGFR
|
Cardiovascular Disease
Neurological Disease
|
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
|
-
- HY-P99908
-
NT-17
|
Interleukin Related
|
Cancer
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
- HY-108801A
-
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
-
- HY-P99951
-
-
- HY-P99690
-
-
Cat. No. |
Product Name |
Type |
-
- HY-NP117
-
Human Type II collagen, immunization grade
|
Native Proteins
|
Highly purified Type II collagen, from human sternal cartilage (Human Type II collagen, immunization grade) is an immune grade collagen derived from human sternal cartilage, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP189
-
Human IgG
|
Native Proteins
|
Human Immunoglobulin G (Human IgG) is an immunoglobulin that plays a protective role in humoral immunity by producing antibody responses against specific pathogens (such as Bacteroides forsythus and Prevotella intermedia). Human Immunoglobulin G (Human IgG) can also serve as an antibody standard for quantitative analysis in enzyme-linked immunosorbent assays (ELISA). Human Immunoglobulin G antibody levels can be used for research on rheumatoid arthritis (RA) and periodontal disease .
|
-
- HY-NP191
-
Human IgM
|
Native Proteins
|
Human Immunoglobulin M (Human IgM) is an antibody secreted by the adaptive immune system in response to a foreign antigen. Human Immunoglobulin M is the main class of immunoglobulin that is secreted into the circulation, in the early stages of a primary antibody response. Human Immunoglobulin M is a pentamer of five IgG equivalents, with 10 Fab fragments and therefore 10 antigen-binding sites. Human Immunoglobulin M is an activator of complement .
|
-
- HY-NP116
-
Human Type I collagen, immunization grade
|
Native Proteins
|
Highly purified Type I collagen, from human placenta (Human Type I collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP118
-
Human Type III collagen, immunization grade
|
Native Proteins
|
Highly purified Type III collagen, from human placenta (Human Type III collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP121
-
Human Type XI collagen, immunization grade
|
Native Proteins
|
Highly purified Type XI collagen, from human sternal cartilage (Human Type XI collagen, immunization grade) is an immune grade collagen derived from human sternal cartilage, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP120
-
Human Placenta Type V collagen, immunization grade
|
Native Proteins
|
Highly purified Type V collagen, from human placenta (Human Placenta Type V collagen, immunization grade) is an immune grade collagen derived from human placenta, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-NP119
-
Human Amnion Type V collagen, immunization grade
|
Native Proteins
|
Highly purified Type V collagen, from human amnion (Human Amnion Type V collagen, immunization grade) is an immune grade collagen derived from human amnion, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
|
-
- HY-163551
-
|
Biochemical Assay Reagents
|
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3203A
-
|
TNF Receptor
|
Inflammation/Immunology
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-108905
-
Human IGF-I; FK 780
|
IGF-1R
|
Metabolic Disease
|
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
|
-
- HY-P5276
-
|
PD-1/PD-L1
|
Cancer
|
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production .
|
-
- HY-P4664
-
|
Peptides
|
Inflammation/Immunology
|
VHLTP is the N-terminal pentapeptide of human hemoglobin beta. VHLTP binds to cell membranes and serves as a ligand for anti-HbA1c antibodies .
|
-
- HY-P3203
-
-
- HY-P10628
-
|
Amyloid-β
|
Neurological Disease
|
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
|
-
- HY-P10458
-
Human/rat 5-LO (130-149)
|
Lipoxygenase
|
Others
|
5-Lipoxygenase blocking peptide (Human/rat 5-LO 130-149) is a specific sequence fragment of 5-lipoxygenase (5-LOX), which can be utilized to prepare an antibody against 5-LOX .
|
-
- HY-P4025
-
|
HIV
|
Others
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
- HY-P10109A
-
hG6PI (325-339) hydrochloride
|
Peptides
|
Inflammation/Immunology
|
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
-
- HY-P10109
-
|
Peptides
|
Inflammation/Immunology
|
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
-
- HY-P5201S1
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-P3560
-
TV 4710
|
Apoptosis
|
Inflammation/Immunology
|
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
|
-
- HY-P10056
-
Human ezrin peptide (324-337)
|
HIV
HCV
HPV
Influenza Virus
Interleukin Related
|
Infection
Inflammation/Immunology
|
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
|
-
- HY-P3385
-
SCB-313
|
Drug Derivative
|
Others
|
Rilunermin alfa (SCB-313) is an active compound. Rilunermin alfa can be used for various biochemical studies .
|
-
- HY-K0213
-
1 Publications Verification
|
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.
|
-
- HY-K0214
-
2 Publications Verification
|
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P990496
-
COM701
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990615
-
LOP628 antibody
|
c-Kit
|
Inflammation/Immunology
|
Anti-c-Kit Antibody (LMJ729) (LOP628 antibody) is a CHO-expressed human antibody that targets SCFR/c-Kit/CD117. The predicted molecular weight (MW) of Anti-c-Kit Antibody (LMJ729) is 150 kDa. The isotype control for Anti-c-Kit Antibody (LMJ729) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990464
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990402
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-DLL4 Antibody is a CHO-expressed human antibody targeting DLL4. The Anti-DLL4 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-DLL4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990343
-
|
Beta-secretase
|
Inflammation/Immunology
|
Anti-BACE1 Antibody is a CHO-expressed human antibody that targets BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. The isotype control for Anti-BACE1 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990357
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990535
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990578
-
DS-6157 antibody
|
G Protein-coupled Receptor Kinase (GRK)
|
Inflammation/Immunology
|
Anti-GPR20 Antibody (DS-6157 antibody) is a human antibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990429
-
|
Ferroportin
|
Inflammation/Immunology
|
Anti-Hepcidin/HAMP Antibody is a CHO-expressed human antibody that targets Hepcidin/HAMP. Anti-Hepcidin/HAMP Antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990485
-
|
PCSK9
|
Inflammation/Immunology
|
Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990540
-
CSL346
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990405
-
|
Ephrin Receptor
|
Inflammation/Immunology
|
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990325
-
|
ATP-binding cassette (ABC) transporters
|
Inflammation/Immunology
|
Anti-ABCB5 Antibody is a CHO-expressed human antibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990421
-
|
HBV
|
Inflammation/Immunology
|
Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990476
-
|
Notch
|
Inflammation/Immunology
|
The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990500
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-ROBO1 Antibody is a CHO-expressed human antibody that targets ROBO1. The Anti-ROBO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ROBO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990497
-
|
CGRP Receptor
|
Inflammation/Immunology
|
Anti-RAMP3 Antibody is a CHO expressed human antibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990520
-
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Anti-TLR7 Antibody is a CHO-expressed human antibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990407
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-EPOR Antibody is a humanized antibody expressed in CHO, targeting EPOR. The predicted molecular weight (MW) of Anti-EPOR Antibody is 150 kDa. The isotype control for Anti-EPOR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990351
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990389
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990468
-
|
MMP
|
Inflammation/Immunology
|
Anti-MMP9 Antibody is a CHO-expressed human antibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990513
-
|
Microtubule/Tubulin
|
Inflammation/Immunology
|
The Anti-STOP1 Antibody is a human antibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990418
-
|
Smo
|
Inflammation/Immunology
|
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990536
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-TSPAN8 Antibody is a human source antibody expressed in CHO cells, targeting TSPAN8. The Anti-TSPAN8 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TSPAN8 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990510
-
|
Ferroportin
|
Inflammation/Immunology
|
Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO, targeting SLC40A1. The predicted molecular weight (MW) of Anti-SLC40A1 Antibody is 150 kDa.
|
-
- HY-P990504
-
|
PAI-1
|
Inflammation/Immunology
|
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990461
-
MSC-1
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-LIF Antibody (MSC-1) is a CHO-expressed human antibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990533
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-TPSAB1 Antibody is a CHO-expressed human antibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990481
-
|
PACAP Receptor
|
Inflammation/Immunology
|
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990534
-
K1-70
|
TSH Receptor
|
Inflammation/Immunology
|
Anti-TSHR Antibody (K1-70) is a CHO-expressed human antibody that targets TSHR. Anti-TSHR Antibody (K1-70) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.54 kDa. For the isotype control of Anti-TSHR Antibody (K1-70), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990495
-
|
Phosphatase
|
Inflammation/Immunology
|
Anti-PTPRC/CD45 Antibody is a CHO-expressed human antibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990442
-
CNTO 607
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990446
-
DISC0280
|
Interleukin Related
|
Inflammation/Immunology
|
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990529
-
|
TNF Receptor
|
Inflammation/Immunology
|
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed human antibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990471
-
|
Tyrosinase
|
Inflammation/Immunology
|
The Anti-MSPR/RON/CD136 Antibody is a human antibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990327
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990480
-
|
LDLR
|
Inflammation/Immunology
|
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990427
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHO cells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990466
-
|
Mesothelin
|
Inflammation/Immunology
|
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990431
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990521
-
AGX101 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
The Anti-TM4SF1 Antibody is a CHO-expressed human antibody that targets TM4SF1. The Anti-TM4SF1 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TM4SF1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990366
-
|
Glycosidase
|
Inflammation/Immunology
|
The Anti-CHI3L1 Antibody is a human antibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990498
-
DISC-0974
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
The Anti-RGMC/HFE2 Antibody (DISC-0974) is a CHO-expressed human antibody that targets RGMC/HFE2. The Anti-RGMC/HFE2 Antibody (DISC-0974) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.66 kDa. For the isotype control of the Anti-RGMC/HFE2 Antibody (DISC-0974), please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990368
-
AB1-11
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990374
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990532
-
|
Wnt
|
Inflammation/Immunology
|
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990460
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990544
-
AJW 200; AJvW 2
|
Integrin
|
Inflammation/Immunology
|
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990467
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990665
-
SGN-CD352A antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-SLAMF6 Antibody (h20F3ec) (SGN-CD352A antibody) is a human-derived antibody expressed in CHO targeting SLAMF6/CD352. Anti-SLAMF6 Antibody (h20F3ec) has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.9 kDa. The isotype control for Anti-SLAMF6 Antibody (h20F3ec) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990474
-
|
Trk Receptor
|
Inflammation/Immunology
|
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2a heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990395
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990384
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-CSF3R/G-CSFR Antibody is a CHO-expressed human antibody that targets CSF3R/G-CSFR. Anti-CSF3R/G-CSFR Antibody contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CSF3R/G-CSFR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990425
-
|
Adenylate Cyclase
|
Inflammation/Immunology
|
Anti-GPR73/PROKR1 Antibody is a CHO-expressed human antibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990436
-
|
Integrin
|
Inflammation/Immunology
|
The Anti-ICAM3/CD50 Antibody is a human antibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990530
-
hMAK195
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990392
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990528
-
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990381
-
|
c-Fms
|
Inflammation/Immunology
|
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990396
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-CYR61/CCN1 Antibody is a CHO-expressed human antibody that targets CYR61/CCN1. The Anti-CYR61/CCN1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CYR61/CCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990524
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990352
-
|
Scavenger Receptor Class B type I (SR-BI)
|
Inflammation/Immunology
|
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990501
-
|
Wnt
β-catenin
|
Inflammation/Immunology
|
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990579
-
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990664
-
SC-005 antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990605
-
IMGN-779 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-CD33 Antibody (IMGN-779 antibody) is a CHO-expressed humanized antibody targeting Siglec-3/CD33. Anti-CD33 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.6 kDa. The isotype control for Anti-CD33 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990454
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
The Anti-INHBB/Activin B Antibody is a human antibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990478
-
|
CRAC Channel
|
Inflammation/Immunology
|
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990452
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990523
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990349
-
|
CD19
|
Inflammation/Immunology
|
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990393
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL9 Antibody is a humanized antibody expressed in CHO cells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990419
-
|
Amino Acid Decarboxylase
|
Inflammation/Immunology
|
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990439
-
|
IFNAR
|
Inflammation/Immunology
|
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990360
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990337
-
|
Chloride Channel
|
Inflammation/Immunology
|
Anti-ANO1/TMEM16A Antibody is a CHO-expressed human antibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990502
-
|
Sodium Channel
|
Inflammation/Immunology
|
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990391
-
|
CXCR
|
Inflammation/Immunology
|
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990364
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990400
-
|
Discoidin Domain Receptor
|
Inflammation/Immunology
|
Anti-DDR1/CD167a Antibody is a CHO-expressed human antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990516
-
|
PKA
|
Inflammation/Immunology
|
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990519
-
CNTO5429
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed human antibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990408
-
|
EGFR
|
Inflammation/Immunology
|
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed human antibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990503
-
|
Sodium Channel
|
Inflammation/Immunology
|
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990390
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990517
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990372
-
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990346
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-CAPRIN1 Antibody is a humanized antibody expressed in CHO, targeting CAPRIN1. The Anti-CAPRIN1 Antibody comes with a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CAPRIN1 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990344
-
|
Bcl-2 Family
|
Inflammation/Immunology
|
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990505
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990451
-
SNG-CD123A
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed human antibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990447
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-IL-20 Antibody is a Chinese hamster ovary (CHO) expressed humanized antibody that targets IL-20. The Anti-IL-20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990332
-
CNTO 2125
|
Amyloid-β
|
Inflammation/Immunology
|
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990353
-
TRX1
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990403
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990627
-
MEDI-547 antibody
|
Ephrin Receptor
|
Inflammation/Immunology
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990659
-
RG-7841 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-LY6E Antibody (MLYE4489A) (RG-7841 antibody) is a humanized antibody expressed in CHO targeting Ly6E. Anti-LY6E Antibody (MLYE4489A) contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-LY6E Antibody (MLYE4489A) can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990630
-
OBT076
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
The Anti-LY75/CD205 Antibody (MEN1309) is a human antibody expressed in CHO cells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990479
-
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
|
Anti-OX2R/CD200R1 Antibody is a CHO-expressed human antibody that targets OX2R/CD200R1. The predicted molecular weight (MW) of Anti-OX2R/CD200R1 Antibody is 146.58 kDa. The isotype control for Anti-OX2R/CD200R1 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990417
-
|
Antifolate
|
Inflammation/Immunology
|
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990398
-
|
Integrin
|
Inflammation/Immunology
|
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990426
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990558
-
BMS-986148 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990459
-
|
Kallikrein
|
Inflammation/Immunology
|
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990394
-
|
CXCR
|
Inflammation/Immunology
|
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990340
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990341
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-B7-H4/VTCN1 Antibody is a CHO-expressed human antibody that targets B7-H4/VTCN1. The Anti-B7-H4/VTCN1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990609
-
- HY-P990369
-
AB3-7
|
HCV
|
Inflammation/Immunology
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99242
-
- HY-P991075
-
|
NAMPT
|
Inflammation/Immunology
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990531
-
|
TNF Receptor
|
Inflammation/Immunology
|
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990415
-
|
FGFR
|
Inflammation/Immunology
|
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990542
-
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990413
-
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990434
-
|
Histone Methyltransferase
|
Inflammation/Immunology
|
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990326
-
Ab-14E1
|
TGF-β Receptor
|
Inflammation/Immunology
|
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed human antibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990472
-
H5B14
|
c-Met/HGFR
|
Inflammation/Immunology
|
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990397
-
FA19-1
|
VEGFR
|
Inflammation/Immunology
|
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990385
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHO cells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990315
-
AGS-16C
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHO cells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990362
-
|
Cadherin
|
Inflammation/Immunology
|
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990543
-
|
VEGFR
|
Inflammation/Immunology
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990387
-
|
Ser/Thr Protease
|
Inflammation/Immunology
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990486
-
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990489
-
IMC-2C5
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-PDGFRB/CD140b Antibody (IMC-2C5) is a humanized antibody expressed in CHO cells that targets PDGFRB/CD140b. Anti-PDGFRB/CD140b Antibody (IMC-2C5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for Anti-PDGFRB/CD140b Antibody (IMC-2C5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990646
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
The Anti-TPBG Antibody (PF-06263507) is a humanized antibody expressed in CHO cells that targets TPBG. PF-06263507 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for PF-06263507 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990618
-
|
Ferroportin
|
Inflammation/Immunology
|
LY2928057 is a CHO-expressed human antibody that targets SLC40A1/Ferroportin. The predicted molecular weight (MW) of LY2928057 is 150 kDa. The isotype control for LY2928057 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990378
-
|
Complement System
|
Inflammation/Immunology
|
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990568
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
CLN-619 is a human antibody expressed in CHO that targets MICA. CLN-619 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.06 kDa. The isotype control for CLN-619 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990546
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Apamistamab is a CHO-expressed human antibody that targets PTPRC/CD45. Apamistamab carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.52 kDa. The isotype control for Apamistamab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990629
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
MEDI-578 is a CHO-expressed human antibody that targets NGF/bNGF. MEDI-578 has a huIgG2a heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-578 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990635
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
NGM-120 is a CHO-expressed human antibody that targets GFRAL. NGM-120 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.7 kDa. The isotype control for NGM-120 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990322
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
AMG-811 is a CHO expressed human antibody that targets IFNg. AMG-811 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for AMG-811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990411
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed human antibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990324
-
3F6-9G5
|
Adenosine Receptor
|
Inflammation/Immunology
|
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990617
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
LY2787106 is a CHO-expressed human antibody that targets Hepcidin/HAMP. LY2787106 has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for LY2787106 can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990653
-
|
CCR
|
Inflammation/Immunology
|
R707 is a human antibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990563
-
|
Interleukin Related
|
Inflammation/Immunology
|
CDP-484 is a CHO-expressed human antibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990598
-
BMS-986253; HuMax-IL-8
|
CXCR
|
Inflammation/Immunology
|
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99278
-
MT 201; Anti-Human EPCAM Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
|
- HY-P990597
-
|
FGFR
|
Inflammation/Immunology
|
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990674
-
|
GLUT
|
Inflammation/Immunology
|
VB1-050 is a human antibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990619
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
LY3022855 is a CHO-expressed human antibody that targets CSF1R/M-CSFR/CD115. LY3022855 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LY3022855 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990551
-
NG-101
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Atinumab (NG-101) is a CHO-expressed human antibody that targets RTN4/NOGO. Atinumab (NG-101) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Atinumab (NG-101) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990654
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Radretumab is a CHO-expressed humanized antibody that targets Fibronectin. Radretumab has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Radretumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990319
-
|
NAMPT
|
Inflammation/Immunology
|
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). For other indications, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990566
-
Rasdegafusp alfa
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
CDX-1401 is a CHO-expressed human-derived antibody targeting LY75/CD205/DEC-205. CDX-1401 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CDX-1401 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990023
-
- HY-P990623
-
BMS-936559
|
PD-1/PD-L1
|
Inflammation/Immunology
|
MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990657
-
RO5458640
|
TNF Receptor
|
Inflammation/Immunology
|
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990603
-
RG-6290
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
IMC-C103C is a human antibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990621
-
IMC-TR1
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
LY3022859 (IMC-TR1) is a CHO-expressed human antibody that targets TBFbR2. LY3022859 (IMC-TR1) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 143 kDa. The isotype control for LY3022859 (IMC-TR1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990587
-
|
CD28
|
Inflammation/Immunology
|
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990636
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
NGM-313 is a CHO-expressed human antibody targeting Klotho Beta. NGM-313 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for NGM-313 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990616
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
LY2525623 is a humanized antibody expressed in CHO targeting IL-23. LY2525623 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for LY2525623 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990669
-
|
Interleukin Related
|
Inflammation/Immunology
|
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990564
-
BAY-103356; CDP-571
|
TNF Receptor
|
Inflammation/Immunology
|
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990600
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Icatolimab is a CHO-expressed humanized antibody targeting BTLA/CD272. Icatolimab contains huIgG4SP type heavy chains and huκ type light chains, with a predicted molecular weight (MW) of 146 kDa. The isotype control for Icatolimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990637
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
NGM-621 is a CHO-expressed human antibody that targets Complement C3. NGM-621 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.04 kDa. The isotype control for NGM-621 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990575
-
RG-7598
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
DFRF4539A (RG-7598) is a human-derived antibody expressed in CHO that targets FcRH5/IRTA2/CD307e. DFRF4539A (RG-7598) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DFRF4539A (RG-7598) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991120
-
|
TNF Receptor
|
Cancer
|
Balertatug is a human IgG1K antibody targeting CD70. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
- HY-P990675
-
|
VEGFR
|
Inflammation/Immunology
|
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990591
-
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990614
-
|
Myosin
|
Inflammation/Immunology
|
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990611
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990589
-
|
Trk Receptor
|
Inflammation/Immunology
|
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990608
-
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
|
CD3
|
Inflammation/Immunology
|
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990620
-
|
VEGFR
|
Inflammation/Immunology
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990677
-
|
CCR
|
Inflammation/Immunology
|
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990561
-
|
Interleukin Related
|
Inflammation/Immunology
|
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990638
-
|
CXCR
|
Inflammation/Immunology
|
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991121
-
- HY-P990639
-
|
CXCR
|
Inflammation/Immunology
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990562
-
|
Interleukin Related
|
Inflammation/Immunology
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990633
-
5G-12
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
NC-318 (5G-12) is a human-derived antibody expressed by CHO, targeting Siglec-15/CD33L3. NC-318 (5G-12) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.98 kDa. The isotype control for NC-318 (5G-12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990586
-
FOR46
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
FG-3246 (FOR46) is a humanized antibody expressed in CHO cells that targets CD46. FG-3246 (FOR46) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for FG-3246 (FOR46) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990672
-
U3-1784
1 Publications Verification
|
FGFR
|
Inflammation/Immunology
|
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990555
-
|
CD47
|
Inflammation/Immunology
|
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990645
-
|
Cadherin
|
Inflammation/Immunology
|
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990547
-
|
Interleukin Related
|
Inflammation/Immunology
|
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990670
-
Eltivutabart
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
TTX-030 is a humanized antibody expressed in CHO cells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990647
-
|
Interleukin Related
|
Inflammation/Immunology
|
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990624
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
MEDI-2045 is a humanized antibody expressed in CHO cells that targets IL-4Ra/CD124. MEDI-2045 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-2045 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990313
-
|
CXCR
Interleukin Related
|
Inflammation/Immunology
|
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990559
-
|
TNF Receptor
|
Inflammation/Immunology
|
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990676
-
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990625
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
MEDI-3617 is a humanized antibody expressed in CHO cells, targeting Ang2/ANGPT2/Angiopoietin2. MEDI-3617 has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-3617 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990321
-
MEDI 8968
|
Interleukin Related
|
Inflammation/Immunology
|
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990317
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990445
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-13Ra2/CD213a2 is a CHO-expressed human antibody that targets IL-13Ra2/CD213a2. The predicted molecular weight (MW) of Anti-IL-13Ra2/CD213a2 is 150 kDa. The isotype control for Anti-IL-13Ra2/CD213a2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990622
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990632
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
MVT-5873 is a humanized antibody expressed in CHO cells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990649
-
TRU-015
|
CD20
|
Inflammation/Immunology
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P9916
-
Anti-Human IL6Rα, Human Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
- HY-P9938
-
|
CGRP Receptor
|
Others
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
- HY-P99514
-
AGEN1884
|
CTLA-4
|
Cancer
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
- HY-P990643
-
|
Integrin
|
Inflammation/Immunology
|
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99057
-
CDX-1127
|
TNF Receptor
|
Cancer
|
Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
- HY-P99057A
-
|
TNF Receptor
|
Cancer
|
Varlilumab (anti-CD27) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
- HY-P99474
-
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
- HY-P991048
-
|
c-Fms
|
Cancer
|
AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P99040
-
JNJ-61610588
|
VISTA
|
Cancer
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
- HY-P9967
-
BIIB037
|
Amyloid-β
|
Neurological Disease
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
- HY-P99460
-
- HY-P99039
-
MEDI9447
|
CD73
|
Cancer
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
- HY-P99424
-
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
- HY-P99179
-
|
Inhibitory Antibodies
|
Cancer
|
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .
|
- HY-108810
-
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
- HY-P9974
-
OMP-18R5
|
Wnt
|
Cancer
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
- HY-P990100
-
- HY-P99041
-
ABX-EGF
|
EGFR
|
Cancer
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
- HY-P990574
-
|
Histone Methyltransferase
|
Inflammation/Immunology
|
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99041A
-
|
EGFR
|
Cancer
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
- HY-P99184
-
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
- HY-P990607
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P9957
-
ABthrax
|
Bacterial
|
Infection
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
- HY-P991119
-
|
Interleukin Related
|
Cancer
|
Balekafusp alfa is an IgG1K human antibody against IL-2 with anti-tumor activity. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
- HY-P99246
-
- HY-P990506
-
- HY-P990658
-
- HY-P990482
-
- HY-P990336
-
- HY-P990441
-
- HY-P990483
-
- HY-P990354
-
- HY-P990347
-
- HY-111965
-
- HY-P990552
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
ATN-658 is a humanized antibody expressed in CHO cells that targets PLAUR/uPAR/CD87. ATN-658 contains muIgG1 heavy chain and mκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for ATN-658 can be referenced as Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990514
-
- HY-P990493
-
- HY-P990487
-
- HY-P990358
-
- HY-P990386
-
- HY-P990538
-
- HY-P990437
-
- HY-P990339
-
- HY-P990470
-
- HY-P990443
-
- HY-P990404
-
- HY-P990430
-
- HY-P990522
-
- HY-P990572
-
- HY-P990365
-
- HY-P990473
-
- HY-P990376
-
- HY-P990525
-
- HY-P990458
-
- HY-P990406
-
- HY-P990560
-
- HY-P990348
-
- HY-P990448
-
- HY-P990570
-
- HY-P990518
-
- HY-P990453
-
- HY-P990373
-
- HY-P990484
-
- HY-P990537
-
- HY-P990477
-
- HY-P990494
-
- HY-P990432
-
- HY-P990449
-
- HY-P990323
-
- HY-P990585
-
- HY-P990492
-
- HY-P990545
-
- HY-P990491
-
- HY-P990410
-
- HY-P990641
-
- HY-P990457
-
- HY-P990388
-
- HY-P990490
-
- HY-P990469
-
- HY-P990335
-
- HY-P990359
-
- HY-P990465
-
- HY-P990401
-
- HY-P990463
-
- HY-P990329
-
- HY-P990350
-
- HY-P990550
-
- HY-P990424
-
- HY-P990512
-
- HY-P990462
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-LILRB4/ILT3/CD85k Antibody is a CHO-expressed humanized antibody that targets LILRB4/ILT3/CD85k. The predicted molecular weight (MW) of Anti-LILRB4/ILT3/CD85k Antibody is 144.36 kDa.
|
- HY-P990515
-
- HY-P990361
-
- HY-P990593
-
- HY-P990409
-
- HY-P990444
-
- HY-P990345
-
- HY-P990549
-
- HY-P990380
-
- HY-P990338
-
- HY-P990527
-
- HY-P990342
-
- HY-P990668
-
- HY-P990581
-
- HY-P990440
-
- HY-P990499
-
- HY-P990438
-
- HY-P990660
-
- HY-P990355
-
- HY-P990331
-
- HY-P990610
-
- HY-P990488
-
- HY-P990507
-
- HY-P99431
-
Alomfilimab; SAR 445256
|
CD28
|
Inflammation/Immunology
Cancer
|
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
|
- HY-P990455
-
- HY-P990334
-
- HY-P990377
-
- HY-P990435
-
- HY-P990423
-
- HY-P990433
-
- HY-P990333
-
- HY-P990475
-
- HY-P990456
-
- HY-P99631
-
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
- HY-P990379
-
- HY-P991107
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-Dysadherin Antibody is a human antibody expressed in CHO cells, targeting dysadherin. Anti-Dysadherin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99271
-
Anti-Human F3 Recombinant Antibody
|
ADC Antibody
|
Cancer
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
- HY-P991109
-
PF-06647263 antibody
|
Transmembrane Glycoprotein
|
Neurological Disease
|
Anti-EFNA4 Antibody (PF-06647263 antibody) is a human antibody expressed in CHO cells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99632
-
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
- HY-P9805
-
MERS-3A1; MERS Antibody-3A1
|
SARS-CoV
|
Infection
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
- HY-P991108
-
HKT288 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a human antibody expressed in CHO cells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990841
-
|
Inhibitory Antibodies
|
Others
|
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1, κ human antibody, targeting to human pan-Glypican. The recommend isotype control of Anti-pan-Glypican Antibody (HS20): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P991102
-
|
CD3
|
Cancer
|
Anti-MUC17 Antibody is a human antibody expressed in CHO cells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991105
-
|
Dynamin
|
Others
|
Anti-Clathrin Heavy Chain Antibody is a human antibody expressed in CHO cells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991098
-
|
Trk Receptor
|
Neurological Disease
|
Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991104
-
|
Integrin
|
Metabolic Disease
|
Anti-EMMPRIN/CD147 Antibody is a human antibody expressed in CHO cells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991103
-
|
Interleukin Related
|
Inflammation/Immunology
|
Anti-IL-25 Antibody is a human antibody expressed in CHO cells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991101
-
|
Amyloid-β
|
Neurological Disease
|
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991204
-
|
PSMA
|
Cancer
|
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99232
-
5F9 Monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
- HY-108730
-
Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
|
- HY-P991047
-
JR-141 antibody (uncoupled from iduronate 2-sulfatase)
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99990
-
- HY-P99001
-
- HY-P99002
-
- HY-P991100
-
|
Cadherin
|
Cancer
|
Anti-CDH17/Cadherin-17 Antibody (10C12) is a human antibody expressed in CHO cells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991196
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990966
-
- HY-P990965
-
- HY-P991082
-
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99992
-
- HY-P991197
-
|
CD3
|
Cancer
|
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-108730A
-
- HY-P99175
-
|
CD47
|
Cancer
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
- HY-P990412
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Anti-F8/Factor VIII Antibody is a CHO-expressed human antibody that targets F8/Factor VIII. Anti-F8/Factor VIII Antibody has a huIgG4 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-F8/Factor VIII Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99994
-
- HY-P99996
-
- HY-P99998
-
- HY-P991202
-
|
TSH Receptor
|
Endocrinology
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991191
-
- HY-P99266
-
Anti-Human CD4 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
- HY-P991177
-
|
c-Met/HGFR
|
Cancer
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990964
-
- HY-P990056
-
- HY-P99205
-
|
ADC Antibody
|
Cancer
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
- HY-P99355
-
Anti-ACVR2B Reference Antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
- HY-P99995
-
- HY-P99997
-
- HY-P99447
-
|
Bacterial
|
Infection
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
- HY-P990963
-
- HY-P990058
-
- HY-P990967
-
- HY-P9908
-
- HY-P99699
-
- HY-P991182
-
|
CCR
|
Inflammation/Immunology
|
Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody that targets CCR8. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991072
-
MAPP-66
|
HIV
HSV
|
Infection
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99987
-
- HY-P99457
-
- HY-P990727
-
- HY-P990066
-
- HY-P990053
-
- HY-P991106
-
LY-3076226 antibody
|
FGFR
|
Cancer
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991175
-
- HY-P9909
-
- HY-P990063
-
|
Inhibitory Antibodies
|
Others
|
Mevonlerbart is an IgG4κ antibody targeting human Felcat allergen 1. Felcat allergen 1 is an allergen protein.
|
- HY-P991185
-
|
c-Met/HGFR
|
Cancer
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991171
-
- HY-P991165
-
|
Fc Receptor (FcR)
|
Others
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99195
-
|
Trk Receptor
|
Inflammation/Immunology
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
- HY-P990754
-
|
c-Kit
|
Inflammation/Immunology
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99347
-
- HY-P99867
-
MEDI 573
|
IGF-1R
|
Others
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
- HY-P9S0009
-
- HY-P990065
-
- HY-P99200
-
- HY-P9927A
-
- HY-P99199
-
NI-0401
|
CD3
|
Inflammation/Immunology
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
- HY-P991174
-
|
TREM receptor
|
Inflammation/Immunology
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99263
-
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
- HY-P99214
-
KBPA101
|
Bacterial
|
Infection
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
- HY-P99274
-
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
|
IGF-1R
|
Cancer
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
- HY-P99305
-
- HY-P9964
-
|
EGFR
|
Cancer
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
- HY-P990047
-
AMG133 antibody
|
GLP Receptor
|
Metabolic Disease
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
- HY-P990774
-
- HY-P990728
-
|
CD74
|
Inflammation/Immunology
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990760
-
- HY-P991115
-
|
Trk Receptor
|
Others
|
Amdokitug is an anti-MUSK human IgG1 λ monoclonal antibody. Recommend Isotype Controls: Human IgG1 Lambda2, Isotype Control (HY-P990096) .
|
- HY-P991060
-
|
Transmembrane Glycoprotein
|
Cancer
|
Cergutuzumab is a fully human IgG1 antibody that targets CEACAM5. The isotype control for Cergutuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991117
-
|
Factor Xa
|
Cardiovascular Disease
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991164
-
|
Antifolate
|
Inflammation/Immunology
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99364
-
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
|
Cancer
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
- HY-P990044
-
- HY-P99408
-
- HY-P990074
-
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
|
- HY-P990725
-
|
SARS-CoV
|
Inflammation/Immunology
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991116
-
- HY-P991022
-
- HY-P991025
-
- HY-P991020
-
- HY-P990768
-
|
SARS-CoV
|
Inflammation/Immunology
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990898
-
- HY-P990705
-
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991187
-
|
Transmembrane Glycoprotein
|
Cancer
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991170
-
|
SARS-CoV
|
Infection
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990943
-
- HY-P990769
-
- HY-P99533
-
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
- HY-P990043
-
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
- HY-P991184
-
|
Inhibitory Antibodies
|
Cancer
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990750
-
|
LAG-3
|
Inflammation/Immunology
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99993
-
- HY-P990080
-
|
CTLA-4
|
Cancer
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
- HY-P99745
-
- HY-P99508
-
IBI939
|
Inhibitory Antibodies
|
Cancer
|
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .
|
- HY-P99617
-
REGN3767
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
- HY-P990915
-
- HY-P990940
-
- HY-P991011
-
- HY-P990982
-
|
CCR
|
Inflammation/Immunology
|
HY-P990982 is an CCL17-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P990927
-
- HY-P991021
-
- HY-P991007
-
- HY-P990977
-
|
Nectin-4
|
Inflammation/Immunology
|
HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991002
-
- HY-P990944
-
- HY-P990942
-
- HY-P990998
-
- HY-P990918
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
HY-P990918 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990937
-
- HY-P991012
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991012 is an TNFRSF4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990999
-
- HY-P991035
-
- HY-P990941
-
|
Antifolate
|
Inflammation/Immunology
|
HY-P990941 is an FOLR1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99485
-
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
- HY-P990922
-
- HY-P990909
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990909 is an ERBB2-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990924
-
|
HBV
|
Inflammation/Immunology
|
HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990897
-
- HY-P990973
-
- HY-P990996
-
|
CD276/B7-H3
|
Inflammation/Immunology
|
HY-P990996 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991010
-
|
CCR
|
Inflammation/Immunology
|
HY-P991010 is an CCL24-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990970
-
- HY-P991008
-
- HY-P99653
-
VAY-736
|
TNF Receptor
|
Cancer
|
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
|
- HY-P99604
-
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
- HY-P99646
-
MEDI6570
|
LOX-1
|
Metabolic Disease
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
- HY-P991059
-
|
Influenza Virus
|
Infection
|
VIS-410 is a fully human IgG1 antibody that targets influenza A virus. The isotype control for VIS-410 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99353
-
Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
- HY-P990756
-
|
SARS-CoV
|
Inflammation/Immunology
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990777
-
- HY-P990950
-
- HY-P990766
-
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P991031
-
- HY-P990711
-
|
SARS-CoV
|
Inflammation/Immunology
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P99272
-
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
- HY-P99156
-
BMS-986016
|
LAG-3
|
Cancer
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
- HY-P990068
-
SRF617
|
NTPDase
|
Cancer
|
Perenostobart is a human immunoglobulin G4-kappa, anti-ENTPD1/CD39 monoclonal antibody. Perenostobart is an immunostimulant and antineoplastic .
|
- HY-P9929
-
|
Bacterial
|
Infection
Inflammation/Immunology
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
- HY-P9918
-
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
- HY-P9939
-
KRN23
|
Inhibitory Antibodies
|
Others
Cancer
|
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia .
|
- HY-P9903
-
BMS-936558; ONO-4538; MDX-1106
|
PD-1/PD-L1
|
Cancer
|
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
|
- HY-P99642
-
- HY-P991159
-
|
EGFR
|
Cancer
|
Ruzaltatug is a humanized IgG1 antibody targeting ERBB3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99603
-
SEA-CD40
|
Inhibitory Antibodies
|
Cancer
|
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
|
- HY-P99964
-
AGS15C; Ha15-10ac12; Ha15-10ac12.1
|
Inhibitory Antibodies
|
Cancer
|
Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer .
|
- HY-P990968
-
|
LAG-3
|
Inflammation/Immunology
|
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990971
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990971 is an TNFRSF9-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990951
-
- HY-P990923
-
|
CCR
|
Inflammation/Immunology
|
HY-P990923 is an CCR8-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990976
-
|
LAG-3
|
Inflammation/Immunology
|
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99398
-
BPS 804
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer .
|
- HY-P99104
-
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
|
- HY-P99318
-
LT 1009; Anti-Human S1P Recombinant Antibody
|
LPL Receptor
|
Cancer
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
- HY-P99357
-
REGN1193; Anti-GCGR Reference Antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
- HY-P99188
-
CNTO 888
|
CCR
|
Cancer
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
|
- HY-P99586
-
REGN2222
|
RSV
|
Infection
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
- HY-P990947
-
- HY-P99286
-
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
- HY-P99703
-
17.1.41
|
HBV
|
Infection
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
- HY-P99194
-
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
- HY-P990911
-
- HY-P990900
-
|
CD73
|
Inflammation/Immunology
|
HY-P990900 is an NT5E-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990745
-
- HY-P991009
-
|
CD73
|
Inflammation/Immunology
|
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990975
-
- HY-P991064
-
3BNC-117
|
HIV
|
Infection
|
Lafuvitug (3BNC-117) is a fully human IgG1 antibody that targets envelope glycoprotein gp120 protein. The isotype control for Lafuvitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99473
-
BI-505
|
Integrin
|
Cancer
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
- HY-P99323
-
BTT 1023; Anti-Human AOC3 Recombinant Antibody
|
VAP-1
|
Inflammation/Immunology
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
- HY-P990069
-
SRK-181
|
Inhibitory Antibodies
|
Cancer
|
Linavonkibart (SRK 181) is a high-affinity, fully human antibody that selectively binds to latent TGFβ1 and inhibits its activation. Linavonkibart plays an important role in cancer .
|
- HY-P99870
-
ASLAN004; CSL-334; MK-6105
|
Interleukin Related
|
Others
|
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
|
- HY-P990917
-
- HY-P99167
-
HCD122
|
TNF Receptor
|
Cancer
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
- HY-P99622
-
IMC-20D7S
|
Tyrosinase
|
Cancer
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
- HY-P99860
-
- HY-P99262
-
BAX69; Anti-Human MIF Recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
- HY-P99307
-
AMG-203; Anti-Human CSF2 Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
- HY-P99760
-
BCD-145
|
CTLA-4
|
Cancer
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
- HY-P99288
-
Pamrevlumab; Anti-Human CTGF Recombinant Antibody
|
Apoptosis
|
Cancer
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
- HY-P99484
-
AGEN 1181
|
CTLA-4
|
Cancer
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
- HY-P99320
-
OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody
|
Notch
|
Cancer
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
- HY-P991140
-
|
Claudin
|
Cancer
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
- HY-P990032
-
EOS-448; EOS884448; GSK4428859A
|
Transmembrane Glycoprotein
|
Cancer
|
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity .
|
- HY-P9925
-
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
- HY-P990954
-
|
CD47
|
Inflammation/Immunology
|
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9915
-
Anti-Human CD38, Human Antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
- HY-P99275
-
Human Anti-ERBB3 Recombinant Antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
- HY-P99366A
-
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
- HY-P99695
-
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
- HY-P99423
-
ADG 20
|
SARS-CoV
|
Infection
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
- HY-P99168
-
|
IFNAR
|
Inflammation/Immunology
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
- HY-P99375
-
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
- HY-P990876
-
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
- HY-P990033
-
CC-95251; BMS-986351
|
CD47
|
Cancer
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
- HY-P990031
-
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
- HY-P99411
-
SHP647
|
Integrin
|
Inflammation/Immunology
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
- HY-P991160
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
Suvonstobart is a monoclonal antibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .
|
- HY-P99207
-
KB 003
|
SARS-CoV
|
Cancer
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
- HY-P99900
-
MSL-109
|
CMV
|
Infection
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
- HY-P99700
-
IBI-188
|
Inhibitory Antibodies
|
Cancer
|
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
|
- HY-P990921
-
- HY-P991126
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
- HY-P991139
-
|
CTLA-4
|
Cancer
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
- HY-P99461
-
ISU-104
|
EGFR
|
Cancer
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
- HY-P990009
-
NIS-793
|
TGF-beta/Smad
|
Cancer
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
|
- HY-P9922
-
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
- HY-P991152
-
|
Interleukin Related
|
Inflammation/Immunology
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P9915A
-
Anti-Human CD38, Human Antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
- HY-P991058
-
BMS-986315
|
Checkpoint Kinase (Chk)
|
Cancer
|
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99178
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
- HY-P99955
-
- HY-P99792
-
NM57; rhRIG
|
RABV
|
Infection
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
- HY-P990021
-
|
Bacterial
|
Others
|
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
|
- HY-P99257
-
ASKP 1240
|
TNF Receptor
|
Inflammation/Immunology
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: ?0.24?nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
|
- HY-P991071
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
AK-001 is a fully human IgG1 antibody that targets Siglec-8. VRC-01 can be used for the study of chronic rhinosinusitis with nasal polyps. The isotype control for AK-001 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991065
-
JNJ-375; JNJ-64179375; JNJ-9375
|
Thrombin
|
Cardiovascular Disease
|
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99260
-
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
|
TNF Receptor
|
Cancer
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
- HY-P99880
-
LFB-R593
|
Inhibitory Antibodies
|
Others
|
Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells .
|
- HY-P991124
-
|
Factor XI
|
Cardiovascular Disease
|
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
|
- HY-P991131
-
|
Inhibitory Antibodies
|
Cancer
|
Daretabart is a humanized IgG1K antibody targeting GD2, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
- HY-P99036
-
- HY-P99389
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD) .
|
- HY-P991135
-
|
CCR
|
Cancer
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
- HY-P99764
-
REGN-3471
|
Filovirus
|
Infection
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
- HY-P9901
-
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
- HY-P99795
-
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
- HY-P991143
-
|
Claudin
|
Cancer
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
- HY-P991195
-
|
TNF Receptor
|
Cancer
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P99102
-
10-1074
|
HIV
|
Infection
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
- HY-P991145
-
|
SLC39 (Zinc Transporter)
|
Cancer
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
- HY-P991137
-
|
Ser/Thr Protease
|
Metabolic Disease
|
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
|
- HY-P990912
-
- HY-P990014
-
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
- HY-P99007
-
BAY 1179470
|
FGFR
|
Cancer
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
- HY-P99936
-
LJM716
|
EGFR
|
Cancer
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
- HY-P990953
-
- HY-P990913
-
bsAb7075; REGN-7075
|
EGFR
|
Inflammation/Immunology
|
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99661
-
|
Interleukin Related
|
Cancer
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
- HY-P991130
-
|
Amyloid-β
|
Neurological Disease
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
- HY-P99197
-
CP-751871
|
IGF-1R
|
Cancer
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
- HY-P99265
-
HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
Mapatumumab (HGS-ETR1) is a fully human IgG2 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
|
- HY-P991125
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
- HY-P991192
-
|
TNF Receptor
|
Cancer
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
- HY-P991156
-
|
Ras
|
Inflammation/Immunology
|
Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
|
- HY-P991127
-
|
Complement System
|
Inflammation/Immunology
|
Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
- HY-P9920A
-
|
VEGFR
|
Cancer
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
- HY-P991061
-
SRF-114
|
CCR
|
Cancer
|
CHS-114 (SRF-114) is a fully human IgG1 antibody that targets CCR8. CHS-114 has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991057
-
|
CD47
|
Cancer
|
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991123
-
|
Adenylate Cyclase
|
Inflammation/Immunology
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
- HY-P9927
-
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
- HY-P99415
-
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
- HY-P99770
-
514-G3
|
Bacterial
|
Infection
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
- HY-P991128
-
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
|
- HY-P99710
-
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
- HY-P99807
-
BCD-100
|
PD-1/PD-L1
|
Cancer
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
- HY-P990094
-
CSL311
|
c-Fms
|
Inflammation/Immunology
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
- HY-P99643
-
UCB6114
|
Dan family
|
Cancer
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
- HY-P99294
-
AMG 479; Human Anti-IGF1R Recombinant Antibody
|
IGF-1R
|
Cancer
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
- HY-P99846
-
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
- HY-P991161
-
|
Complement System
|
Inflammation/Immunology
|
Tanruprubart is a monoclonal antibody targeting human complement C1q. Tanruprubart specifically binds to complement C1q, inhibiting the initiation of the classical complement activation pathway and exerting immunosuppressive activity. Tanruprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
- HY-P991138
-
|
Interleukin Related
|
Inflammation/Immunology
|
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
|
- HY-P99056
-
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
- HY-P99786
-
REGN3918
|
Complement System
|
Metabolic Disease
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
- HY-P99322
-
LFG316; Anti-Human C5 Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
- HY-P99110
-
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
- HY-P991141
-
|
VEGFR
|
Cancer
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
- HY-P99114
-
|
PD-1/PD-L1
|
Cancer
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
- HY-P99519
-
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
- HY-P991134
-
|
IGF-1R
|
Inflammation/Immunology
|
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
|
- HY-P99450
-
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
- HY-P99556
-
AZD8895
|
SARS-CoV
|
Infection
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
- HY-P99376
-
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
- HY-P9931
-
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
- HY-P991114
-
|
FLT3
|
Inflammation/Immunology
|
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
|
- HY-P991040
-
|
Inhibitory Antibodies
|
Cancer
|
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
|
- HY-P99020
-
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
- HY-P99220
-
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
- HY-P991069
-
|
HIV
|
Infection
|
VRC-01 is a fully human IgG1 antibody that targets envelope glycoprotein gp120 Protein. VRC-01 blocks viral entry by partially mimicking the interaction of the CD4 receptor with HIV-1 gp120 envelope glycoprotein. The isotype control for VRC-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99669
-
MDX-060
|
TNF Receptor
|
Cancer
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
- HY-P9919
-
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
- HY-P99218
-
Sch 717454; 19D12
|
IGF-1R
|
Cancer
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
|
- HY-P99541
-
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
- HY-P99836
-
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
- HY-P99191
-
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
- HY-P99299
-
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
- HY-P99486
-
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
- HY-P990015
-
VIR-3434
|
HBV
|
Infection
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P9958
-
AMG-162
|
NF-κB
Caspase
Apoptosis
RANKL/RANK
|
Endocrinology
Cancer
|
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
- HY-P991129
-
|
Interleukin Related
|
Inflammation/Immunology
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P991144
-
|
Interleukin Related
|
Inflammation/Immunology
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
- HY-P990928
-
|
CD3
|
Inflammation/Immunology
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
- HY-P99688
-
AL001
|
Neurotensin Receptor
|
Cancer
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
- HY-P99913
-
|
c-Fms
|
Inflammation/Immunology
Cancer
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
- HY-P991142
-
|
MHC
|
Inflammation/Immunology
Cancer
|
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
|
- HY-P99637
-
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
- HY-P991201
-
|
Interleukin Related
|
Inflammation/Immunology
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991068
-
|
Transmembrane Glycoprotein
|
Cancer
|
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99342
-
REGN10987
|
SARS-CoV
|
Infection
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
- HY-P9961
-
|
CD20
|
Cancer
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
|
- HY-P99876
-
OMP-336B11
|
Inhibitory Antibodies
|
Others
|
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .
|
- HY-P9958A
-
|
RANKL/RANK
Apoptosis
NF-κB
|
Neurological Disease
Endocrinology
Cancer
|
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
- HY-P991070
-
|
TNF Receptor
|
Cancer
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991073
-
|
Amyloid-β
|
Neurological Disease
|
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99344
-
Anti-Human SARS-CoV-2
|
SARS-CoV
|
Infection
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
- HY-P99268
-
SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
- HY-P990078
-
LY3372993
|
Amyloid-β
|
Neurological Disease
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
|
- HY-P99203
-
|
PD-1/PD-L1
|
Cancer
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
- HY-P991173
-
|
Notch
|
Cancer
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99552
-
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
- HY-P990932
-
BI 764532; OBT 620
|
CD3
|
Inflammation/Immunology
|
HY-P990932 is an CD3E/HEK-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .
|
- HY-P99155
-
|
EGFR
|
Cancer
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
- HY-P99772
-
L19TNF
|
TNF Receptor
|
Cancer
|
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
|
- HY-P991054
-
|
Influenza Virus
|
Infection
|
CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC50s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99479
-
L19-IL2
|
Interleukin Related
|
Cancer
|
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity .
|
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
- HY-P99190
-
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
- HY-163480
-
|
CXCR
|
Inflammation/Immunology
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P9919A
-
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
- HY-P99810
-
AVTX-002; AEVI 002; SAR 252067
|
SARS-CoV
|
Cardiovascular Disease
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
- HY-P99518
-
BMS 986089; RG 6206; RO 7239361; BHV2000
|
TGF-beta/Smad
|
Others
|
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
|
- HY-P99055
-
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
- HY-P991146
-
|
Interleukin Related
|
Inflammation/Immunology
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P99877
-
AMG592
|
Inhibitory Antibodies
|
Others
|
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99109
-
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
- HY-P99925
-
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
|
- HY-P990090
-
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
- HY-145644
-
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
- HY-P99189
-
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
- HY-P99551
-
KBSA301; AR-301
|
Antibiotic
|
Infection
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
- HY-P991206
-
- HY-P99583
-
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
- HY-P99833
-
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
|
- HY-P99392
-
|
CD3
|
Cancer
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
- HY-P99111
-
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
- HY-P99410
-
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
- HY-P99165
-
|
IGF-1R
TSH Receptor
|
Endocrinology
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
- HY-P99341
-
REGN10933
|
SARS-CoV
|
Infection
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
- HY-P99509
-
- HY-P99003
-
- HY-P991200
-
|
Claudin
HCV
|
Infection
|
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
|
- HY-P990096
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Human IgG1 lambda2, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1κ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
|
- HY-P9930
-
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
- HY-P99620
-
CT-P22; CT120
|
Influenza Virus
|
Infection
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
- HY-P99759
-
IL-15N72D
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
|
- HY-P99324
-
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
- HY-P990302
-
|
nAChR
|
Others
|
Anti-Human/Rat/Fish AChR Antibody (Mab35) is a rat-derived IgG1 type antibody inhibitor, targeting to human/rat/Fish AChR.
|
- HY-P990833
-
|
Mesothelin
|
Others
|
Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
|
- HY-P9928
-
REGN 727; SAR 236553
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
|
- HY-P99359
-
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
- HY-P990239
-
|
Inhibitory Antibodies
|
Others
|
Anti-Human/Mouse GRP78 Antibody (N88) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse GRP78.
|
- HY-P990149
-
|
Tyrosinase
|
Others
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human TYRP1.
|
- HY-P990167
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein.
|
- HY-P990210
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human IL-7 Antibody (M25) is a mouse-derived IgG2b type antibody inhibitor, targeting to mouse/human IL-7.
|
- HY-P990213
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse/human IL-5.
|
- HY-P990238
-
|
EGFR
|
Others
|
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to human/rat HER2.
|
- HY-P990136
-
|
Inhibitory Antibodies
|
Others
|
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to monkey/human CD28.
|
- HY-P990205
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1.
|
- HY-P990138
-
|
CD20
|
Others
|
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to monkey/human CD20.
|
- HY-P991198
-
|
Tim3
|
Cancer
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
- HY-P990189
-
|
MHC
|
Others
|
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MHC class II.
|
- HY-P990251
-
|
MMP
|
Others
|
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.
|
- HY-P990207
-
|
Integrin
|
Others
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.
|
- HY-P990146
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse/rat/human v-H-Ras.
|
- HY-P991042
-
|
IGF-1R
|
Cancer
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
- HY-P99444
-
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
- HY-P990117
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human Osteopontin/SPP1.
|
- HY-P99273
-
|
TNF Receptor
|
Cancer
|
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
|
- HY-P990132
-
|
CD47
|
Others
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
|
- HY-P990805
-
|
HSP
|
Others
|
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b kappa in vivo mouse antibody, targeting to GRP78. The recommend isotype control of Anti-Human/Mouse GRP78 Antibody (C38): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P9928A
-
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
|
- HY-P99304
-
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
|
Cancer
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
- HY-P990236
-
|
CD28
|
Others
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
|
- HY-P990196
-
|
P-glycoprotein
|
Others
|
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MDR-1/CD243.
|
- HY-P990133
-
|
TNF Receptor
|
Others
|
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154.
|
- HY-P990169
-
|
PD-1/PD-L1
|
Others
|
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can be used in WB and FC experiments in the context of human and mouse.
|
- HY-P990198
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Mac-2/Galectin-3.
|
- HY-P990173
-
|
PD-1/PD-L1
|
Others
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.
|
- HY-P99453
-
|
ADC Antibody
|
Cancer
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
- HY-P990301
-
|
Amyloid-β
|
Others
|
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b, λ type antibody inhibitor, targeting to Amyloid-beta.
|
- HY-P991207
-
- HY-P99017
-
- HY-P990297
-
|
CCR
|
Others
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse/rat/human CCL2/MCP-1.
|
- HY-P990202
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human LRP1/CD91.
|
- HY-P9977
-
JNJ-61186372
|
EGFR
|
Cancer
|
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
- HY-P990107
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an anti-mouse/human/rat/monkey/hamster/canine/bovine IgG antibody inhibitor of TGF-β . The recommend isotype control of Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P9917
-
Anti-Human IL6R, Humanized Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
- HY-P99785
-
HLX20
|
PD-1/PD-L1
|
Cancer
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
- HY-P990847
-
|
E-Selectin
|
Others
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-164153
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
- HY-P990850
-
|
c-Myc
|
Others
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990865
-
|
CD28
|
Others
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990144
-
|
Inhibitory Antibodies
|
Others
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse/human VLA-4/CD49d.
|
- HY-P99526
-
- HY-P990826
-
|
Inhibitory Antibodies
|
Others
|
Anti-YB-1 Antibody (21A3) is a kind of mouse IgG1 chimeric antibody, targeting to human YB-1. The recommend isotype control of Anti-YB-1 Antibody (21A3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990830
-
|
Inhibitory Antibodies
|
Others
|
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human MUC16. The recommend isotype control of Anti-MUC16 Antibody (VK8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990873
-
|
DNA/RNA Synthesis
|
Others
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990840
-
|
Glycoprotein VI
|
Others
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990870
-
|
CD19
|
Others
|
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990839
-
|
IFNAR
|
Others
|
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to human IFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990842
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P9998
-
UB421
|
HIV
|
Cancer
|
Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
- HY-P990869
-
|
Inhibitory Antibodies
|
Others
|
Anti-CD1a Antibody (OKT-6) is a kind of mouse IgG1 chimeric antibody, targeting to human CD1a. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990859
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990843
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to human Glycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990864
-
|
Inhibitory Antibodies
|
Others
|
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CD3. The recommend isotype control of Anti-CD3 Antibody (OKT-3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990856
-
|
Transferrin Receptor
|
Others
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990846
-
|
Inhibitory Antibodies
|
Others
|
Anti-Fy3 Antibody (MIMA-29) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Fy3. The recommend isotype control of Anti-Fy3 Antibody (MIMA-29): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990845
-
|
Inhibitory Antibodies
|
Others
|
Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Ganglioside GD2. The recommend isotype control of Anti-Ganglioside GD2 Antibody (14G2a): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P99264
-
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
- HY-P99335
-
Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
- HY-P990604
-
IMGC-936 antibody
|
MMP
|
Inflammation/Immunology
|
Anti-ADAM9 Antibody (MGA021) (IMGC-936 antibody) is a humanized antibody expressed in CHO cells that targets ADAM9. Anti-ADAM9 Antibody (MGA021) is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.62 kDa. The isotype control for Anti-ADAM9 Antibody (MGA021) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990356
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990836
-
|
Interleukin Related
|
Others
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990827
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990868
-
|
CD2
|
Others
|
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990832
-
|
MHC
|
Others
|
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990860
-
|
Inhibitory Antibodies
|
Others
|
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD40. The recommend isotype control of Anti-CD40 Antibody (G28.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990861
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-164152
-
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
- HY-164154
-
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
- HY-P99332
-
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
- HY-P99391
-
ABT-700
|
Inhibitory Antibodies
|
Cancer
|
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .
|
- HY-P99328
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
- HY-P990855
-
|
Integrin
|
Others
|
Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P99276
-
Anti-Human CA-125 Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc) .
|
- HY-P990772
-
- HY-P990732
-
- HY-P990734
-
- HY-P990746
-
- HY-P990749
-
- HY-P99211
-
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
- HY-P99397
-
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
- HY-P990853
-
|
Inhibitory Antibodies
|
Others
|
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM5. The recommend isotype control of Anti-CEACAM5 Antibody (4H11-8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P9804
-
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
- HY-P990851
-
|
c-Kit
|
Others
|
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human c-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990852
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990838
-
|
Inhibitory Antibodies
|
Others
|
Anti-IL-12 p70 Antibody (20C2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-12 p70. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P99254
-
1E10
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer .
|
- HY-P990328
-
XT-M4
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990858
-
|
CD47
|
Others
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990862
-
|
CD3
|
Others
|
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990867
-
|
Insulin Receptor
|
Others
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P9981
-
XmAb5574; MOR00208; Tafasitamab-cxix
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
- HY-P990013
-
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
- HY-P990054
-
|
CD20
|
Cancer
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
- HY-P990753
-
- HY-P99616
-
MOR-202
|
CD38
|
Cancer
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
- HY-P990781
-
SM03
|
CD22
|
Inflammation/Immunology
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990686
-
|
TNF Receptor
|
Inflammation/Immunology
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990697
-
ARX-788
|
EGFR
|
Inflammation/Immunology
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990729
-
|
CD19
|
Inflammation/Immunology
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990764
-
|
Integrin
|
Inflammation/Immunology
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990747
-
|
CD38
|
Inflammation/Immunology
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990739
-
|
CTLA-4
|
Inflammation/Immunology
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990744
-
- HY-P991166
-
|
Mucin
|
Others
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P990762
-
- HY-P990767
-
- HY-P990687
-
- HY-P990712
-
|
Insulin Receptor
|
Inflammation/Immunology
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990775
-
|
CTLA-4
|
Inflammation/Immunology
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99280
-
Anti-Human IL17A/IL-17F Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
- HY-P990872
-
|
Inhibitory Antibodies
|
Others
|
Anti-CA19-9 Antibody (1116-NS-19-9) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CA19-9. The recommend isotype control of Anti-CA19-9 Antibody (1116-NS-19-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990863
-
|
Inhibitory Antibodies
|
Others
|
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody, targeting to human CD32/FcγRIIA. The recommend isotype control of Anti-CD32/FcγRIIA Antibody (IV.3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990848
-
|
Inhibitory Antibodies
|
Others
|
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CTLA-4/CD152. The recommend isotype control of Anti-CTLA-4/CD152 Antibody (BN13): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P99010A
-
|
Interleukin Related
FGFR
|
Cancer
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
- HY-P990837
-
|
Interleukin Related
|
Others
|
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P99851
-
SPECIFID
|
Inhibitory Antibodies
|
Cancer
|
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
|
- HY-P991163
-
|
CD3
Claudin
|
Cancer
|
Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers .
|
- HY-P990696
-
- HY-P991169
-
|
Factor Xa
|
Cardiovascular Disease
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P990758
-
|
VEGFR
|
Inflammation/Immunology
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990737
-
|
CXCR
|
Inflammation/Immunology
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99034
-
- HY-P990713
-
- HY-P990773
-
|
CD28
|
Inflammation/Immunology
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99014
-
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
- HY-P9914
-
Anti-Human C5, Humanized Antibody
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
- HY-P990684
-
- HY-P990771
-
|
CD73
|
Inflammation/Immunology
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990704
-
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990755
-
|
EGFR
|
Inflammation/Immunology
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99356
-
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
- HY-P99393
-
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
- HY-P99038
-
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
- HY-P990726
-
|
TNF Receptor
|
Inflammation/Immunology
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990743
-
- HY-P990702
-
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990854
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990831
-
|
Mucin
|
Others
|
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to human MUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
|
- HY-P990541
-
|
VEGFR
|
Inflammation/Immunology
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-141607
-
- HY-P99515
-
- HY-P99160
-
|
Transmembrane Glycoprotein
|
Cancer
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
- HY-P99638
-
- HY-P990690
-
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990770
-
- HY-P990761
-
- HY-P990700
-
RO-7247669
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990694
-
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990701
-
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99234
-
|
Interleukin Related
ADC Antibody
|
Cancer
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
- HY-P99013
-
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
- HY-P99279
-
Anti-Human Phosphatidylserine Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
|
- HY-P990829
-
|
Transmembrane Glycoprotein
|
Others
|
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human NKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990834
-
|
Inhibitory Antibodies
|
Others
|
Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MAGEC2/CT10. The recommend isotype control of Anti-MAGEC2/CT10 Antibody (LX-CT10.5): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-145626
-
BA302
|
ADC Antibody
|
Cancer
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
- HY-P99187
-
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
- HY-P9950
-
Olizumab; rhuMab-E25
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .
|
- HY-P990751
-
- HY-P99656
-
MCDS0593A
|
ADC Antibody
|
Cancer
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
- HY-P99813
-
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
- HY-141606
-
BAY 94-9343
|
Microtubule/Tubulin
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
|
- HY-P99354
-
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
- HY-P99612
-
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
- HY-P990849
-
|
Inhibitory Antibodies
|
Others
|
Anti-CSF1R/CD115 Antibody (2-4A5-4) is a kind of rat IgG1, κ chimeric antibody, targeting to human CSF1R/CD115. The recommend isotype control of Anti-CSF1R/CD115 Antibody (2-4A5-4): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990871
-
|
Integrin
|
Others
|
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990844
-
|
Complement System
|
Others
|
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990857
-
|
Integrin
|
Others
|
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990752
-
REGN-5678
|
CD28
|
Inflammation/Immunology
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99186
-
|
Inhibitory Antibodies
|
Others
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
- HY-108852
-
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
- HY-P99313
-
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
- HY-P99796
-
ATN-103
|
TNF Receptor
|
Inflammation/Immunology
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
- HY-P990691
-
- HY-P99909
-
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990692
-
|
CD3
|
Inflammation/Immunology
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P9905
-
Cetuximab
Maximum Cited Publications
39 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
- HY-P99209
-
MEDI-524
|
RSV
|
Infection
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
- HY-P991132
-
|
VEGFR
|
Cardiovascular Disease
Cancer
|
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
|
- HY-P99465
-
- HY-P99832
-
c13C6-FR1
|
Filovirus
|
Infection
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
- HY-P990866
-
|
Inhibitory Antibodies
|
Others
|
Anti-CD25/IL-2Rα Antibody (7G7B6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD25/IL-2Rα. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990835
-
|
Inhibitory Antibodies
|
Others
|
Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody, targeting to human LFA-1α/CD11a. The recommend isotype control of Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P99530
-
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
- HY-P99858
-
AB154
|
Inhibitory Antibodies
|
Cancer
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer .
|
- HY-P99151
-
|
ADC Antibody
TNF Receptor
|
Cancer
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
- HY-P99302
-
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
|
- HY-P990526
-
|
TNF Receptor
|
Inflammation/Immunology
|
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990936
-
- HY-P990933
-
- HY-P990926
-
- HY-P990906
-
- HY-P99337
-
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
- HY-P99857
-
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
- HY-P990957
-
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9979
-
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
- HY-P990929
-
|
Mesothelin
|
Inflammation/Immunology
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99607
-
IDEC-151
|
HIV
|
Inflammation/Immunology
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
- HY-P9S0008
-
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
- HY-P990995
-
|
Tau Protein
|
Inflammation/Immunology
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9966
-
MGA271
|
CD276/B7-H3
|
Cancer
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
- HY-P990027
-
|
ADC Antibody
|
Cancer
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
- HY-P991154
-
|
VEGFR
PD-1/PD-L1
|
Cancer
|
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascular endothelial growth factor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .
|
- HY-P990060
-
Mim8
|
Factor Xa
|
Cardiovascular Disease
|
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
|
- HY-P99736
-
BI-754111
|
LAG-3
|
Cancer
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
- HY-P990363
-
PTA001_A4
|
Cadherin
|
Inflammation/Immunology
|
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99550
-
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
- HY-P991150
-
|
Interleukin Related
|
Inflammation/Immunology
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P99442
-
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
- HY-P99895
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
- HY-P990961
-
|
VEGFR
PD-1/PD-L1
|
Inflammation/Immunology
|
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99797
-
JR-141
|
Transferrin Receptor
|
Neurological Disease
|
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
|
- HY-P99662
-
MLN0264; TAK-264
|
Antibody-Drug Conjugates (ADCs)
Guanylate Cyclase
Apoptosis
|
Cancer
|
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
|
- HY-P991168
-
|
Amyloid-β
CCR
|
Neurological Disease
Inflammation/Immunology
|
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
|
- HY-P990993
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990978
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991013
-
- HY-P990979
-
- HY-P990904
-
|
CCR
|
Inflammation/Immunology
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990984
-
- HY-P991038
-
|
CD28
|
Inflammation/Immunology
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990919
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990960
-
- HY-P990931
-
- HY-P991014
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990946
-
- HY-P990914
-
|
CCR
|
Inflammation/Immunology
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99365
-
ALXN1210
|
Complement System
|
Metabolic Disease
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
- HY-P990945
-
|
CTLA-4
|
Inflammation/Immunology
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991026
-
- HY-P990908
-
|
CCR
|
Inflammation/Immunology
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99196
-
|
c-Met/HGFR
|
Cancer
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
- HY-P991162
-
|
Interleukin Related
|
Inflammation/Immunology
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P990930
-
|
CD22
|
Inflammation/Immunology
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990949
-
|
c-Met/HGFR
|
Inflammation/Immunology
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99252
-
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
- HY-P99325
-
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
|
- HY-P99668
-
|
PD-1/PD-L1
|
Cancer
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
- HY-P990828
-
|
Inhibitory Antibodies
|
Others
|
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human PD-L1/B7-H1. The recommend isotype control of Anti-PD-L1/B7-H1 Antibody (29E.2A3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990994
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991203
-
|
Guanylate Cyclase
|
Cancer
|
PF-07062119 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits GUCY2C, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P990925
-
|
CD3
|
Inflammation/Immunology
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990962
-
|
EGFR
|
Inflammation/Immunology
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99222
-
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
- HY-P990934
-
- HY-P99648
-
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
- HY-P991000
-
- HY-P991001
-
- HY-P99115
-
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
- HY-P990916
-
- HY-P990902
-
- HY-P99945
-
- HY-P99652
-
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
- HY-P9801
-
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
- HY-P9934
-
C7E3
|
Integrin
|
Cardiovascular Disease
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
- HY-P9807
-
SARS-CR3022; SARS-CoV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
- HY-P99346
-
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
- HY-P99306
-
DS 1024
|
EGFR
|
Cancer
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
- HY-P991155
-
|
CD3
TNF Receptor
|
Cancer
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
- HY-P991063
-
BNT-313
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99437
-
KN-026
|
EGFR
|
Cancer
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
|
- HY-P991019
-
- HY-P99768
-
TTAC-0001
|
VEGFR
|
Cancer
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
- HY-P991147
-
|
PD-1/PD-L1
|
Cancer
|
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
|
- HY-P990910
-
- HY-P990955
-
|
CD3
|
Inflammation/Immunology
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991032
-
- HY-P990952
-
- HY-P990983
-
- HY-P990948
-
- HY-P99399
-
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
- HY-P990956
-
- HY-P9991
-
TST001
|
Gap Junction Protein
|
Cancer
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
- HY-P991136
-
|
Inhibitory Antibodies
|
Cancer
|
Etuptamig is a chimeric monoclonal antibody of immunoglobulin λ-chain-γ1, λ-chain-γ3 targeting human natural killer cell cytotoxicity receptor 1 (NCR1). Etuptamig is promising for research of various cancers .
|
- HY-P991050
-
AK-1967
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99902
-
FAP-IL2v
|
Interleukin Related
|
Cancer
|
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
|
- HY-P99327
-
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
- HY-P99385
-
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
- HY-P9954
-
|
CD3
|
Cancer
|
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
|
- HY-P990899
-
|
CD47
|
Inflammation/Immunology
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P991024
-
|
TNF Receptor
|
Inflammation/Immunology
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99763
-
BGB-A1217
|
Inhibitory Antibodies
|
Cancer
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .
|
- HY-P991023
-
|
CD47
|
Inflammation/Immunology
|
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99776
-
XmAb-13676
|
CD20
CD3
|
Cancer
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
- HY-P99336
-
BI-RR 0001; Anti-Human IL6 Recombinant Antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
- HY-P99333
-
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
- HY-P991149
-
|
TNF Receptor
|
Cancer
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
- HY-P99595
-
AGS15E; ASG-15ME; 1vcMMAE
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
|
- HY-P991172
-
|
CD3
Transmembrane Glycoprotein
|
Cancer
|
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
|
- HY-P99371
-
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
- HY-P99756
-
MEDI8897
|
RSV
|
Infection
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
- HY-P990554
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
BHQ-880 is a humanized antibody expressed in CHO cells, targeting DKK1. The predicted molecular weight (MW) of BHQ-880 is 142.96 kDa. The isotype control for BHQ-880 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99680
-
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
- HY-P991062
-
Gensci-059
|
CD47
|
Cancer
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99417
-
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
- HY-P99162
-
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
- HY-P990571
-
|
CD19
|
Inflammation/Immunology
|
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99378
-
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
- HY-P9803
-
SARS-80R; SARS Antibody-80R
|
SARS-CoV
|
Infection
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
- HY-P99282
-
VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A
|
Apoptosis
|
Cancer
|
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
|
- HY-P991051
-
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990969
-
|
CD3
|
Inflammation/Immunology
|
HY-P990969 is an CD3E/CD4-targeting IgG1?λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99361
-
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
- HY-P990631
-
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P99345
-
TSR-042
|
PD-1/PD-L1
|
Cancer
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
- HY-P99618
-
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
- HY-P990569
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
CM-24 is a humanized antibody expressed in CHO cells, targeting CEACAM1/CD66a. The predicted molecular weight (MW) of CM-24 is 145 kDa. The isotype control for CM-24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990673
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991052
-
|
TNF Receptor
|
Cancer
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990651
-
|
TREM receptor
|
Inflammation/Immunology
|
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991066
-
|
nAChR
|
Neurological Disease
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99349
-
Loncastuximab tesirine-lpyl; ADCT-402
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
|
- HY-P99293
-
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
|
Cancer
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
- HY-P990782
-
|
Aminoacyl-tRNA Synthetase
|
Inflammation/Immunology
|
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
|
- HY-P991151
-
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
- HY-P990662
-
|
Interleukin Related
|
Inflammation/Immunology
|
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P9806
-
MERS-D12; MERS Antibody-D12
|
SARS-CoV
|
Infection
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
- HY-P990642
-
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990958
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
HY-P990958 is an T cell receptor germline-encoded variable chain Vβ6/β10-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99493
-
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P9984
-
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
- HY-P99163
-
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
- HY-P99407
-
VX 15/2503
|
Inhibitory Antibodies
|
Neurological Disease
Cancer
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
|
- HY-P990318
-
|
VEGFR
|
Inflammation/Immunology
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990093
-
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
- HY-P990017
-
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
- HY-P990594
-
|
Interleukin Related
|
Inflammation/Immunology
|
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990661
-
|
c-Met/HGFR
|
Inflammation/Immunology
|
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990628
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
MEDI-570 is a humanized antibody expressed in CHO that targets ICOS/CD278. MEDI-570 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-570 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99962
-
BGB-A425
|
Mucin
|
Cancer
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
- HY-P990599
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Ibritumomab is a mouse antibody expressed in CHO, targeting CD20/MS4A1. Ibritumomab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Ibritumomab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990678
-
|
TNF Receptor
|
Inflammation/Immunology
|
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990312
-
|
Interleukin Related
|
Inflammation/Immunology
|
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P9933
-
APN-311
|
Inhibitory Antibodies
|
Cancer
|
Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) .
|
- HY-P990595
-
|
Amyloid-β
|
Inflammation/Immunology
|
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990314
-
|
EGFR
|
Inflammation/Immunology
|
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 74.5 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990650
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990719
-
XmAb24306
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
|
- HY-P990602
-
|
Interleukin Related
|
Inflammation/Immunology
|
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990601
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
ICT-01 is a humanized antibody expressed by CHO that targets BTN1A1. ICT-01 has an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.2 kDa. The isotype control for ICT-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99464
-
IMMU-LL 2
|
CD22
|
Cancer
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
- HY-P990567
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Citatuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Citatuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.4 kDa. The isotype control for Citatuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990008
-
Atrosab
1 Publications Verification
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9949
-
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
- HY-P990596
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Hersintuzumab is a CHO-expressed humanized antibody targeting ERBB2/HER2/CD340. Hersintuzumab is equipped with a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Hersintuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99492
-
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P990667
-
|
Integrin
|
Inflammation/Immunology
|
STX-100 is a humanized antibody expressed in CHO cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99248
-
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
- HY-P990656
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
RG-6125 is a humanized antibody expressed in CHO, targeting CDH11/Cadherin-11. RG-6125 has a huIgG2 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for RG-6125 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990573
-
RG-7636
|
Endothelin Receptor
|
Inflammation/Immunology
|
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99575
-
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
- HY-P9999
-
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
- HY-P99737
-
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
- HY-P99008
-
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
|
- HY-P990634
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
NEO-201 is a humanized antibody expressed in CHO cells that targets CEACAM6/CD66c. NEO-201 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.48 kDa. The isotype control for NEO-201 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990592
-
E-6071; HGS-1035
|
CCR
|
Inflammation/Immunology
|
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990311
-
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
AB-25E9 is a humanized antibody expressed in CHO, targeting Siglec-15/CD33L3. The predicted molecular weight (MW) of AB-25E9 is 150 kDa. The isotype control for AB-25E9 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990613
-
CBA-1205
|
Notch
|
Inflammation/Immunology
|
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991067
-
KP-104
|
Complement System
|
Inflammation/Immunology
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
- HY-P99803
-
VAL-1221
|
Glycosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
- HY-P990612
-
AML-01
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991080
-
ASG-5ME Antibody; AGS-5M2
|
ADC Antibody
|
Cancer
|
Anti-SLC44A4 Antibody (ASG-5ME Antibody) is a SLC44A4 targeting antibody that can be used for synthesis of ADC ASG-5ME .
|
- HY-P99103
-
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
- HY-P99780
-
- HY-145643
-
ZRC3308-B10
|
SARS-CoV
|
Infection
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
- HY-P99709
-
LY3300054
|
PD-1/PD-L1
|
Cancer
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
- HY-P99352
-
Anti-MSLN Antibody
|
Mesothelin
ADC Antibody
|
Cancer
|
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
|
- HY-P9926
-
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
- HY-P99630
-
MM-302
|
EGFR
|
Cancer
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
- HY-P99383
-
REMD-477; AMG-477
|
GCGR
|
Metabolic Disease
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
|
- HY-P990086
-
|
Interleukin Related
|
Cancer
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
- HY-P990067
-
ATOR-1017
|
TNF Receptor
|
Cancer
|
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
|
- HY-145641
-
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
- HY-P99653A
-
|
TNF Receptor
Apoptosis
|
Cancer
|
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
|
- HY-P990708
-
- HY-P991113
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
- HY-P99152
-
|
CD3
|
Inflammation/Immunology
Cancer
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
- HY-P99775
-
ART621; CEP-37247; PN0621
|
TNF Receptor
|
Inflammation/Immunology
|
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
|
- HY-P990896
-
|
ADC Antibody
|
Cancer
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
- HY-P990085
-
|
Tim3
|
Infection
|
Verzistobart is an IgG1κ antibody targeting the hepatitis A virus cellular receptor HAVCR2.
|
- HY-P99654
-
INT-001
|
Inhibitory Antibodies
|
Cancer
|
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) .
|
- HY-P99565
-
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
- HY-P99277
-
Anti-C. difficile Toxin A Recombinant Antibody
|
Inhibitory Antibodies
|
Infection
|
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
|
- HY-P99428
-
NGM282
|
Inhibitory Antibodies
|
Metabolic Disease
|
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .
|
- HY-P99853
-
CR6261
|
Influenza Virus
|
Infection
|
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
|
- HY-P99804
-
MK1654
|
RSV
|
Infection
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
|
- HY-P99159
-
|
Inhibitory Antibodies
|
Cancer
|
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4 + and CD8 + T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity .
|
- HY-P991157
-
|
RSV
|
Infection
|
Retavibart is a human respiratory syncytial virus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
|
- HY-P99871
-
AK102
|
PCSK9
|
Others
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .
|
- HY-P9980A
-
|
ADC Antibody
TNF Receptor
|
Cancer
|
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
|
- HY-P991193
-
|
MMP
|
|
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
|
- HY-P99499
-
JNJ 63723283; JNJ 3283
|
PD-1/PD-L1
Interleukin Related
TNF Receptor
|
Cancer
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
|
- HY-P991180
-
|
TNF Receptor
|
Cancer
|
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
|
- HY-P99777
-
TTI-621
|
CD47
|
Cancer
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
- HY-P99459
-
BG 9924; TT-47
|
TNF Receptor
|
Inflammation/Immunology
|
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
|
- HY-P99543
-
OPRX-106; PRX-106; TNFR-Fc
|
TNF Receptor
|
Cancer
|
Tulinercept (OPRX-106) is a recombinant TNF receptor fusion protein fused to an IgG1 Fc domain .
|
- HY-P99016
-
|
ADC Antibody
Nectin-4
|
Cancer
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
- HY-P99935
-
PRS-060; AZD1402
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma .
|
- HY-P99799
-
CX-072
|
PD-1/PD-L1
|
Cancer
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
- HY-P990006
-
TEV-48574
|
TNF Receptor
|
Inflammation/Immunology
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
- HY-P990064
-
- HY-P99621
-
NPC-21; EV2038
|
CMV
|
Infection
|
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
|
- HY-P99722
-
REGN3470-3471-3479
|
Filovirus
|
Infection
|
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
|
- HY-P99723
-
BCD-135
|
PD-1/PD-L1
|
Cancer
|
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
|
- HY-P990706
-
ALPN-303
|
TNF Receptor
|
Inflammation/Immunology
|
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
|
- HY-P99414
-
AMG 557
|
CD28
|
Inflammation/Immunology
|
Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors .
|
- HY-P99670
-
- HY-P991190
-
|
TGF-beta/Smad
|
|
AV-380 is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
- HY-P990763
-
- HY-P99844
-
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Cancer
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99386
-
MNRP-1685A
|
Complement System
EGFR
PDGFR
p38 MAPK
|
Cancer
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
|
- HY-P99458
-
CG 10639
|
c-Fms
|
Cancer
|
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
|
- HY-P99887
-
JTX-4014
|
PD-1/PD-L1
|
Cancer
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor .
|
- HY-P99529
-
BAX1810; TAK-752
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
|
- HY-P99472
-
- HY-P99037
-
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
- HY-P99667
-
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
- HY-P99106
-
- HY-P99031
-
CAM 3001
|
c-Fms
|
Cardiovascular Disease
Inflammation/Immunology
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
|
- HY-P99794
-
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
- HY-P99343
-
REGN3470
|
Filovirus
|
Infection
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
|
- HY-P99478
-
|
IFNAR
|
Inflammation/Immunology
|
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
|
- HY-P99720
-
ACE-536; luspatercept–aamt
|
TGF-beta/Smad
|
Metabolic Disease
Cancer
|
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
|
- HY-P99441
-
SRK-015
|
TGF-beta/Smad
|
Neurological Disease
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
|
- HY-P99491
-
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
- HY-P991194
-
|
TNF Receptor
|
Cancer
|
HFB-200301 is an IgG1 antibody targeting tumor necrosis factor receptor 2 (TNFR2). HFB-200301 promotes the activation of TNFR2, thereby activating relevant signaling pathways, such as activating RelA and cRel-containing NF-κB dimers through the classical NF-κB pathway, affecting cell metabolism and gene expression in the presence of sTNF. HFB-200301 is promising for research of cancers .
|
- HY-P99718
-
BAY 1112623
|
ADC Antibody
|
Cancer
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
- HY-P9986
-
MTIG-7192A; RG-6058
|
CD28
|
Inflammation/Immunology
Cancer
|
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) .
|
- HY-P990703
-
- HY-145642
-
ZRC3308-A7
|
SARS-CoV
|
Infection
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
- HY-P99725
-
- HY-P990786
-
|
FLT3
ADC Antibody
|
Cancer
|
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
|
- HY-P99219
-
MEDI-545; MDX 1103
|
IFNAR
|
Inflammation/Immunology
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
|
- HY-P99624
-
CR4098
|
RABV
|
Infection
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
|
- HY-P99815
-
- HY-P99048A
-
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
- HY-P99046
-
|
Inhibitory Antibodies
|
Cancer
|
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study .
|
- HY-P99930
-
|
FGFR
|
Metabolic Disease
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
- HY-P99198
-
- HY-P99608
-
|
HBV
|
Infection
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
- HY-P99433
-
U 85855
|
HIV
|
Infection
|
Alvircept sudotox is a recombinant CD4 derived from Pneumonas aeruginosa exotoxin A. Alvircept sudotox can be used in the research of HIV infections .
|
- HY-P990052
-
MAD-0004J08
|
SARS-CoV
|
Infection
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
- HY-P9952
-
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .
|
- HY-P990959
-
- HY-P99487
-
BR 3FC
|
ADC Antibody
|
Inflammation/Immunology
|
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
|
- HY-P99445
-
APG101; CAN008
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
|
- HY-P99402
-
REGN 2176
|
PDGFR
|
Metabolic Disease
|
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
|
- HY-P99698
-
LDP
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
|
- HY-P99420
-
ALPN-101
|
CD28
|
Inflammation/Immunology
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
- HY-P99924
-
|
GHR
|
Others
|
Efpegsomatropin is a human growth hormone-Fc conjugate peptide. Efpegsomatropin can be used for various biochemical studies.
|
- HY-P99467
-
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
- HY-P99448
-
- HY-P99009
-
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
- HY-P991167
-
|
Bacterial
|
Infection
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
- HY-P99516
-
HLX-06
|
VEGFR
|
Cancer
|
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
|
- HY-P99429
-
BG 9273; Human LFA 3IgG fusion protein; LFA 3TIP
|
Inhibitory Antibodies
|
Others
|
Alefacept (BG 9273) is a human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein. Alefacept can be used for the research of chronic plaque psoriasis .
|
- HY-P99692
-
p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1
|
TNF Receptor
|
Inflammation/Immunology
|
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
|
- HY-P99553
-
42-89-glycoprotein; WAY164339; pMT21:PL85
|
P-selectin
|
Others
|
Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
|
- HY-P99729
-
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
- HY-P990765
-
- HY-P991148
-
|
PD-1/PD-L1
|
Cancer
|
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
|
- HY-P990037
-
|
CD38
|
Cancer
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
- HY-P99053
-
- HY-P991181
-
- HY-P99750
-
CT-P23
|
Influenza Virus
|
Infection
|
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
|
- HY-P99223
-
MEDI-575
|
PDGFR
|
Cancer
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
- HY-P99244
-
ILV 094
|
Interleukin Related
|
Inflammation/Immunology
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
|
- HY-P991186
-
|
Inhibitory Antibodies
|
Cancer
|
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy .
|
- HY-P99226
-
MEDI7734; VIB7734
|
SARS-CoV
|
Cancer
|
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
|
- HY-P991179
-
|
TNF Receptor
|
Cancer
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
- HY-P99360
-
Anti-AXL/UFO Reference Antibody (enapotamab)
|
TAM Receptor
|
Cancer
|
Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .
|
- HY-P990707
-
TTI-622; PF-07901801
|
CD47
|
Inflammation/Immunology
|
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
|
- HY-P99536
-
SL-401
|
Interleukin Related
|
Cancer
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
- HY-P991178
-
|
TNF Receptor
|
Cancer
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
- HY-P99469
-
PB 2452; MEDI 2452
|
Inhibitory Antibodies
|
Metabolic Disease
|
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
|
- HY-P99568
-
RC18
|
TNF Receptor
|
Inflammation/Immunology
|
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .
|
- HY-P99823
-
TA-46; sFGFR3
|
FGFR
|
Others
|
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
|
- HY-P991153
-
|
Virus Protease
|
Infection
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
- HY-P99022
-
|
Amyloid-β
|
Neurological Disease
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
- HY-P990087
-
- HY-P99217
-
AMG 102
|
c-Met/HGFR
|
Cancer
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
- HY-P990310
-
- HY-P99388
-
REGN-1033
|
TGF-beta/Smad
|
Metabolic Disease
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
|
- HY-P990111
-
- HY-P99527
-
ACC-001; PF 05236806
|
Amyloid-β
|
Neurological Disease
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
- HY-P99440
-
CSL-324
|
c-Fms
JAK
STAT
|
Inflammation/Immunology
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
|
- HY-P99771
-
- HY-P99525
-
- HY-P99966
-
|
RANKL/RANK
|
Cancer
|
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .
|
- HY-P99782
-
|
TNF Receptor
|
Inflammation/Immunology
|
Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .
|
- HY-P99208
-
IPH2102
|
Transmembrane Glycoprotein
|
Cancer
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
|
- HY-P99645
-
- HY-P99578
-
HL036337; HBM9036
|
TNF Receptor
|
Inflammation/Immunology
|
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
|
- HY-P99048
-
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
- HY-P990079
-
|
CD28
|
Inflammation/Immunology
|
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .
|
- HY-P99818
-
ACE-031
|
TGF-β Receptor
|
Metabolic Disease
|
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
|
- HY-P9991A
-
|
Gap Junction Protein
|
Cancer
|
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
- HY-P990683
-
- HY-114134
-
rhEPO; EPOCH; Genetical recombination
|
Inhibitory Antibodies
|
Metabolic Disease
Cancer
|
Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research .
|
- HY-P99748
-
|
TGF-β Receptor
|
Inflammation/Immunology
|
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
|
- HY-P99940
-
ABT-122
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
|
- HY-P99296
-
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
EGFR
|
Cancer
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
|
- HY-P99233
-
HuMax-TAC
|
Interleukin Related
|
Cancer
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .
|
- HY-P99316
-
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
- HY-P99590
-
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
- HY-P99456
-
- HY-P99806
-
|
Inhibitory Antibodies
|
Cancer
|
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research .
|
- HY-P99937
-
|
HIV
|
Infection
|
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
|
- HY-P99811
-
CR57
|
RABV
|
Infection
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
- HY-145629
-
|
Lipocalin Family
|
Others
|
Palsucibep pegol is a engineered human lipocalin-2 binding protein. Palsucibep pegol binds to hepcidin .
|
- HY-P99446
-
TACI-Ig; TACI-Fc 5
|
TNF Receptor
|
Inflammation/Immunology
|
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
|
- HY-P990024
-
- HY-P99830
-
KH902
|
VEGFR
|
Cardiovascular Disease
|
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
|
- HY-P99406A
-
|
EGFR
|
Cancer
|
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
|
- HY-P990059
-
|
CD276/B7-H3
|
Cancer
|
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
|
- HY-P99545
-
- HY-P99463
-
AVB-500; AVB-S6-500
|
TAM Receptor
|
Cancer
|
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
|
- HY-P99687
-
AMG 256
|
PD-1/PD-L1
|
Cancer
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
- HY-P99793
-
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
- HY-P990062
-
|
Inhibitory Antibodies
|
Others
|
Freneslerbart is an IgG4κ antibody targeting Felcat allergen 1. Felcat allergen 1 is an allergen protein .
|
- HY-P991055
-
RG-6234; RO-7425781
|
CD3
|
Inflammation/Immunology
|
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99941
-
|
PD-1/PD-L1
|
Cancer
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
- HY-P99496
-
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
- HY-P9992
-
BAY-2315497; PSMA-TTC
|
PSMA
|
Inflammation/Immunology
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
|
- HY-P99754
-
|
Interleukin Related
|
Inflammation/Immunology
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
- HY-P990688
-
- HY-P9996
-
LY3434172
|
PD-1/PD-L1
|
Cancer
|
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
|
- HY-P990073
-
REGN-5093
|
c-Met/HGFR
|
Cancer
|
Davutamig (REGN-5093) is a humanIgG4-kappa, anti-MET bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .
|
- HY-P99672
-
MM 141; MM-005
|
IGF-1R
EGFR
|
Cancer
|
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
|
- HY-P990714
-
|
CD3
|
Inflammation/Immunology
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
- HY-P99663
-
|
TNF Receptor
|
Cancer
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
- HY-P99965
-
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
- HY-P99517
-
JNJ-63898081
|
CD3
|
Cancer
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
- HY-P99931
-
GEN3013
|
CD3
CD20
|
Cancer
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
- HY-P99350
-
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
- HY-P99958
-
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
|
Cancer
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
- HY-108786
-
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
- HY-P3393
-
- HY-108801
-
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
- HY-P99907
-
- HY-108822
-
Arcalyst; IL 1 Trap; Interleukin 1 Trap
|
Interleukin Related
|
Inflammation/Immunology
|
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
|
- HY-P99666
-
|
IFNAR
|
Infection
Cancer
|
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
|
- HY-P99752
-
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
- HY-145633
-
OPT 302; VGX-300
|
VEGFR
|
Cardiovascular Disease
|
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
|
- HY-P3385
-
SCB-313
|
Drug Derivative
|
Others
|
Rilunermin alfa (SCB-313) is an active compound. Rilunermin alfa can be used for various biochemical studies .
|
- HY-112935
-
BAX326; Coagulation Factor IX [Recombinant]
|
Ser/Thr Protease
|
Others
|
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .
|
- HY-118860
-
Org 36286; MK-8962
|
Estrogen Receptor/ERR
|
Endocrinology
|
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
|
- HY-P99919
-
|
Interleukin Related
|
Infection
|
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
|
- HY-P99427
-
alb-IFN
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
|
Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C .
|
- HY-P99840
-
CB-2679d; DalcA; ISU-304
|
Inhibitory Antibodies
|
Others
|
Dalcinonacog alfa is a recombinant FIX factor that can be used in the study of Haemophilia B .
|
- HY-108847
-
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
- HY-P99769
-
SCT-800
|
Factor VIII
|
Metabolic Disease
|
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
|
- HY-P99845
-
MEDI 4920; VIB 4920
|
TNF Receptor
|
Others
|
Dazodalibep (MEDI 4920; VIB 4920) is a fusion protein targeting CD40LG/TNFSF5 fused to human serum albumin ALB/HSA .
|
- HY-P99875
-
- HY-P99879
-
Benegrastim; Bineuta; F 627
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
|
- HY-P99348
-
Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b
|
Apoptosis
|
Cancer
|
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .
|
- HY-P99911
-
- HY-P99665
-
LY-3209590
|
Insulin Receptor
|
Metabolic Disease
|
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
|
- HY-P99928
-
- HY-P99735
-
|
IFNAR
|
Infection
|
Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
|
- HY-112998
-
|
Factor VIII
|
Others
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
- HY-P99974
-
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
Nab-Paclitaxel is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel (Paclitaxel: human albumin=1:9), in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel was associated with higher response rates and better tolerability, with favorable pharmacokinetic properties . (The product size below only indicate the effective content of Paclitaxel. The actual albumin quality depends on the batch. The ratio of each component in this product is Paclitaxel: albumin = 1:7-1:11.)
|
- HY-P99944
-
Retlirafusp alfa
|
PD-1/PD-L1
TGF-β Receptor
|
Cancer
|
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
|
- HY-P99696
-
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
- HY-P99917
-
|
STAT
|
Inflammation/Immunology
|
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
|
- HY-P99934
-
ABBV-621
|
Apoptosis
|
Cancer
|
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
|
- HY-108829
-
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
- HY-P99905
-
|
VEGFR
|
Cardiovascular Disease
Neurological Disease
|
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
|
- HY-P99908
-
NT-17
|
Interleukin Related
|
Cancer
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
- HY-108801A
-
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
- HY-P99951
-
- HY-P99932
-
|
Inhibitory Antibodies
|
Others
|
Eftansomatropin alfa is an antibody targeting the growth hormone receptor (GSH). Eftansomatropin alfa is a fusion protein of GH1 and IGHG4 Fc .
|
- HY-P99690
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P5201S1
-
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
-
- HY-P5201S
-
|
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-153084A
-
|
|
mRNA
|
CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: